Document:

QuickLinks
 -- Click here to rapidly navigate through this document

EXHIBIT 10.14  

 
 

Manufacturing Services Agreement
  
    January 1, 2003    
    

	**
	Certain
portions of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The pages on which such omissions appear contain a legend to such effect. 

  

EXHIBIT 10.14  

 
 

Table of Contents    
    

	ARTICLE 1	 	1
	INTERPRETATION	 	1
	 	  1.1      Definitions	 	1
	 	  1.2      Currency	 	4
	 	  1.3      Sections and Headings	 	4
	 	  1.4      Singular Terms	 	4
	 	  1.5      Schedules	 	5
	ARTICLE 2	 	5
	PATHEON'S MANUFACTURING RESPONSIBILITIES	 	5
	 	  2.1      Manufacturing Services	 	5
	 	  2.2      Standard of Performance	 	6
	ARTICLE 3	 	6
	CEPHALON'S OBLIGATIONS	 	6
	 	  3.1      Payment	 	6
	 	  3.2      Active Materials	 	6
	ARTICLE 4	 	7
	CONVERSION FEES AND COMPONENT COSTS	 	7
	 	  4.1      Fees and Component Costs	 	7
	 	  4.2      Adjustments to Current Year's Pricing	 	7
	 	  4.3      Adjustments to Subsequent Year's Pricing	 	8
	 	  4.4      Adjustments Due to Technical Changes	 	9
	ARTICLE 5	 	9
	ORDERS, DELIVERY, INVOICING, PAYMENT, PRODUCT DEFICIENCIES	 	9
	 	  5.1      Market Outlook	 	9
	 	  5.2      Orders and Forecasts	 	9
	 	  5.3      Reliance by Patheon	 	10
	 	  5.4      Minimum Orders	 	11
	 	  5.5      Shipments	 	11
	 	  5.6      Invoices and Payment	 	11
	 	  5.7      Product Deficiencies	 	11
	ARTICLE 6	 	12
	CO-OPERATION	 	12
	 	  6.1      Quarterly Review	 	12
	 	  6.2      Product Recalls and Returns	 	12
	 	  6.3      Customer Questions and Complaints	 	13
	 	  6.4      Governmental Agencies	 	13
	 	  6.5      Records and Accounting by Patheon	 	13
	 	  6.6      Inspection	 	14
	 	  6.7      Access	 	14
	 	  6.8      Reports	 	14
	 	  6.9      Validation	 	14
	 	  6.10    Quality Compliance	 	14
	 	  6.11    Batch Records	 	15
	ARTICLE 7	 	15
	TERM AND TERMINATION	 	15
	 	  7.1      Initial Term	 	15
	 	 	 

i

 

	 	  7.2      Termination for Cause	 	15
	 	  7.3      Product Discontinuation	 	16
	 	  7.4      Obligations on Termination	 	16
	ARTICLE 8	 	16
	REPRESENTATIONS, WARRANTIES AND COVENANTS	 	16
	 	  8.1      Authority	 	16
	 	  8.2      General	 	17
	 	  8.3      Non-Infringement	 	17
	 	  8.4      Debarred Persons	 	18
	 	  8.5      Permits	 	18
	 	  8.6      Compliance with Laws	 	18
	ARTICLE 9	 	18
	REMEDIES AND INDEMNITIES	 	18
	 	  9.1      Consequential Damages	 	18
	 	  9.2      Limitation of Liability	 	18
	 	  9.3      Patheon	 	19
	 	  9.4      Cephalon	 	19
	 	  9.5      Reasonable Allocation of Risk	 	20
	ARTICLE 10	 	20
	CONFIDENTIALITY	 	20
	 	10.1      Disclosure	 	20
	 	10.2      Use of Information	 	20
	 	10.3      Exceptions	 	20
	 	10.4      Designation of Confidentiality	 	21
	ARTICLE 11	 	21
	DISPUTE RESOLUTION	 	21
	 	11.1      Commercial Disputes	 	21
	 	11.2      Technical Dispute Resolution	 	21
	ARTICLE 12	 	23
	TRADEMARKS	 	23
	 	12.1      Trademarks	 	22
	ARTICLE 13	 	22
	MISCELLANEOUS	 	22
	 	13.1      Intellectual Property	 	22
	 	13.2      Insurance	 	22
	 	13.3      Independent Contractors	 	23
	 	13.4      No Waiver	 	23
	 	13.5      Assignment	 	23
	 	13.6      Force Majeure	 	23
	 	13.7      Additional Product	 	24
	 	13.8      Notices	 	24
	 	13.9      Severability	 	24
	 	13.10    Entire Agreement	 	25
	 	13.11    No Third Party Benefit or Right	 	25
	 	13.12    Execution in Counterparts	 	25
	 	13.13    Governing Law	 	26

ii

 
 

MANUFACTURING SERVICES AGREEMENT    
    

          THIS AGREEMENT made as of the    •     day of January 1, 2003

B
E T W E E N: 

PATHEON INC.,

a corporation existing under the laws of Canada,

(hereinafter referred to as "Patheon"), 

—and— 

CEPHALON, INC.,

a corporation existing under the laws of the State of Delaware, USA,

(hereinafter referred to as "Cephalon"). 

        THIS
AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of
which are acknowledged by each party), and intending to be legally bound the parties agree as follows: 

 
 

ARTICLE 1
  INTERPRETATION    
    

1.1   Definitions. 

        The
following terms shall, unless the context otherwise requires, have the respective meanings set out below and grammatical variations of such terms shall have corresponding meanings: 

"Active Materials" means the materials listed on Schedule C hereto; 

"Active Materials Value" means the value to be attributed to the Active Materials for certain purposes of this Agreement, and Patheon's maximum
liability for the replacement cost of the Active Materials, as set out in Schedule D hereto; 

"Affiliate" means: 

	(a)
	a
business entity which owns, directly or indirectly, a controlling interest in a party to this Agreement, by stock ownership or otherwise; or

	(b)
	a
business entity which is owned by a party to this Agreement, either directly or indirectly, by stock ownership or otherwise; or

	(c)
	a
business entity, the majority ownership of which is directly or indirectly common to the majority ownership of a party to this Agreement; 

"Adverse Experience" means any unfavourable and unintended change in the structure, function, or chemistry of the body temporally associated with any
use of the Products or a derivative thereof, whether or not the adverse experience is considered to be related to the use of the Products, including but not limited to any of the following: an
unexpected side effect, injury, toxicity or sensitivity reaction, which may include an experience of unexpected frequency or severity; an adverse experience occurring in the course of the use of a
drug product in professional practice; an adverse experience occurring in clinical studies; an adverse experience occurring from drug overdose, whether accidental or intentional; an adverse experience
occurring from drug abuse; an adverse experience occurring from drug withdrawal; or any significant failure of expected pharmacological action. 

"Business Day" means a day other than a Saturday, Sunday or a day that is a statutory holiday in the Province of Ontario, Canada and the State of
Pennsylvania; 

 

"cGMPs" means current good manufacturing practices as described in: 

	(a)
	Division
2 of Part C of the Food and Drug Regulations (Canada);

	(b)
	Parts
210 and 211 of Title 21 of the United States' Code of Federal Regulations; and

	(c)
	EC
Directive 91/356/EEC, 

together
with the latest TPD, FDA and EMEA guidance documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time; 

"Cephalon's Technical Information" means the file, for each Product, which is provided by Cephalon to Patheon and which contains documents relating to
such Product, including, without limitation: 

	(a)
	a
detailed description of each Product, including its physical and chemical characteristics and stability;

	(b)
	manufacturing
and packaging directions;

	(c)
	shipping
and storage requirements;

	(d)
	protocols
for validating processes or equipment to produce Products;

	(e)
	quality
control and quality assurance procedures for sampling, testing, documenting and releasing Active Materials, Components and in-process and finished Product;

	(f)
	procedures
for testing the stability of the Product; and

	(g)
	all
environmental, health and safety information relating to the Product including material safety data sheets, incident reports, risk analyses, health concerns, preventative measures
and procedures for waste disposal, 

all
as updated, amended and revised from time to time by Cephalon in accordance with the terms of the Agreement; 

"Cephalon's Trademarks" shall mean PROVIGIL® as well as any other trademark owned or sued by Cephalon in connection with the Products,
including without limitation those trademarks listed in Schedule H. 

"Commencement Date" means January 1, 2003; 

"Components" means, collectively, all packaging components, raw materials and ingredients (including labels, product inserts and other labelling for the
Products), required to be used in order to produce the Products in accordance with Cephalon's Technical Information, other than the Active Materials; 

"Confidential Information" means a party's technology, data, know-how or information whether written or oral, technical or
non-technical, including financial statements,
reports, pricing, trade secrets, secret processes, formulas, customer data (including customer lists), and the like, that is disclosed to the other party; 

"Deficiency Notice" shall have the meaning ascribed thereto in Section 5.7(a); 

"EMEA" means the European Medicine Evaluation Agency; 

"FCA" means free carrier, as that term is defined in INCOTERMS 2000; 

"FDA" means the United States government department known as the Food and Drug Administration; 

2

 

"Firm Orders" has the meaning specified in Section 5.2(b); 

"Intellectual Property" includes, without limitation, rights in patents, patent applications, formulae, trade-marks, trade-mark
applications, trade-names, confidential information, trade secrets, inventions, copyright, industrial designs, know-how and, with respect to Cephalon, Cephalon's Technical Information; 

"Inventory" means all inventories of Components and work-in-process produced or held by Patheon in connection with the
manufacture of the Products but, for greater certainty, does not include the Active Materials; 

"Manufacturing Services" means the manufacturing, quality control, quality assurance and stability testing, packaging and related services, as
contemplated in this Agreement, required to produce Products from Active Materials and Components; 

"Patheon Manufacturing Responsibilities" has the meaning specified in Section 2.2; 

"Products" means the products listed on Schedule A hereto; 

"Technical Agreement" means the agreement to be entered into between the parties hereto setting out the quality assurance standards to be applicable to
the Manufacturing Services provided by Patheon, which agreement attached hereto as Schedule G; 

"Technical Dispute" has the meaning specified in Section 11.2; 

"Third Party Rights" means the Intellectual Property of any third party; 

"TPD" means the Canadian government department known as the Therapeutic Products Directorate; and 

"Year" means the twelve-month period commencing, in the case of the first Year of this Agreement, on the Commencement Date, and thereafter commencing
upon completion of the immediately preceding Year. 

1.2   Currency. 

        Unless
otherwise indicated, all monetary amounts are expressed in this Agreement in the lawful currency of the United States of America. 

1.3   Sections and Headings. 

        The
division of this Agreement into Articles, sections, subsections and Schedules and the insertion of headings are for convenience of reference only and shall not affect the
interpretation of this Agreement. Unless otherwise indicated, any reference in this Agreement to a Section or Schedule refers to the specified Section or Schedule to this Agreement. In this Agreement,
the terms "this Agreement", "hereof", "herein",
"hereunder" and similar expressions refer to this Agreement and not to any particular part, Section, Schedule or the provision hereof. 

1.4   Singular Terms. 

        Except
as otherwise expressly provided herein or unless the context otherwise requires, all references to the singular shall include the plural and vice versa. 

3

 

1.5   Schedules. 

        The
following Schedules are attached to, incorporated in and form part of this Agreement: 

	Schedule A	 	—	 	Products, Minimum Run Quantity, Minimum Annual Volume and Fees
	Schedule B	 	—	 	Stability Testing Fees
	Schedule C	 	—	 	Active Materials
	Schedule D	 	—	 	Active Materials Value
	Schedule E	 	—	 	Batch Numbering and Expiration Dates
	Schedule F	 	—	 	Technical Dispute Resolution
	Schedule G	 	—	 	Technical Agreement
	Schedule H	 	—	 	Cephalon's Trademarks

 
 

ARTICLE 2
  PATHEON'S MANUFACTURING RESPONSIBILITIES    
    

2.1   Manufacturing Services. 

        Patheon
shall provide the Manufacturing Services in North America for the fees specified in Schedules A and B in order to produce Products for Cephalon. In providing the Manufacturing
Services: 

	(a)
	Conversion
of Active Materials and Components. Patheon shall convert Active Materials and Components into Products.

	(b)
	Quality
Control and Quality Assurance. Patheon shall perform the quality control and quality assurance testing specified in the Technical Agreement. Each time Patheon ships Products
to Cephalon, it shall provide Cephalon with a certificate of analysis that sets out the test results for each batch of Products, and that certifies that such batch has been evaluated by Patheon's
Quality Control/Quality Assurance department and that the Products comply with Cephalon's Technical Information;

	(c)
	Components.
Patheon shall purchase and test all Components (with the exception of those that are supplied by Cephalon) at Patheon's expense or as otherwise specified by Cephalon's
Technical Information;

	(d)
	Stability
Testing. Patheon shall conduct stability testing on the Products in accordance with the protocols set out in Cephalon's Technical Information for the separate fees specified
in Schedule B. Patheon shall not make any changes to these testing protocols without prior written approval from Cephalon. In the event that any batch of Products fails stability testing,
Patheon and Cephalon shall jointly determine the proceedings and methods to be undertaken to investigate the causes of such failure, including which party shall bear the cost of such investigation,
provided that Patheon shall not be liable for any such costs unless there has been a failure by it to provide the Manufacturing Services in accordance with the Patheon Manufacturing Responsibilities.
Patheon will provide any and all data and results relating to the stability testing upon request by Cephalon; and

	(e)
	Packaging.
Patheon shall package the Products with labels, product inserts and other packaging as set out in Cephalon's Technical Information. In addition, Patheon shall make
arrangements for and implement the imprinting of batch numbers and expiration dates for each Product shipped. Such batch numbers and expiration dates shall be affixed on the Products and on the
shipping carton of each Product as outlined in Cephalon's Technical 

4

 

	

	Information
and as required by cGMPs. The system used by Patheon for batch numbering and expiration dates is detailed in Schedule E hereto. Cephalon may, in its
sole discretion, make changes to labels, product inserts and other packaging for the Products, which changes shall be submitted by Cephalon to all applicable governmental agencies and other third
parties responsible for the approval of the Products. Patheon's name shall not appear on the label nor anywhere else on the Products unless required by a governmental authority or applicable laws or
regulations. 

2.2   Standard of Performance. 

        Patheon
shall provide the Manufacturing Services in accordance with Cephalon's Technical Information and cGMPs. Patheon's responsibilities and obligations with respect to the provision
of the Manufacturing Services as set forth in this Article 2 are hereinafter referred to as the "Patheon Manufacturing Responsibilities". 

 
 

ARTICLE 3
  CEPHALON'S OBLIGATIONS    
    

3.1   Payment. 

        Pursuant
to the terms of this Agreement, Cephalon shall pay Patheon for the provision of the Manufacturing Services according to the fees specified in Schedules A and B hereto (such fees
being subject to adjustment in accordance with the terms hereof). 

3.2   Active Materials. 

        Cephalon
shall, at its sole cost and expense, deliver the Active Materials to Patheon in sufficient quantities and at such times to facilitate the provision of the Manufacturing Services
by Patheon, which Active Materials shall be held by Patheon on behalf of Cephalon on the terms and subject to the conditions herein contained. The parties acknowledge and agree that title to the
Active Materials shall at all times belong to and remain the property of Cephalon. Patheon agrees that any Active Materials received by it shall only be used by Patheon to provide the Manufacturing
Services. Patheon's liability with respect to any lost or damaged Active Materials shall be as set forth in Section 9.2. 

 
 

ARTICLE 4
  CONVERSION FEES AND COMPONENT COSTS    
    

4.1   Fees and Component Costs. 

        The
fees for the Manufacturing Services (which fees include Component Costs) listed in Schedules A and B are intended by the parties to be fixed for the first year of this Agreement,
subject to the amendments to such fees provided for in this Article 4. 

4.2   Adjustments to Current Year's Pricing. 

        During
any Year of this Agreement, the fees set out in Schedule A shall be subject to adjustment in accordance with the following: 

	(a)
	Volume
Reduction. If at any time and from time to time Patheon determines, acting reasonably and based on the forecasts and Firm Orders received from Cephalon, that the current yearly
run-rate volumes (including, without limitation, any permanent reductions in volumes) relating to a specific Product will constitute no more than [**] of the
minimum annual volume for that Product specified in Schedule A hereto or, if applicable, any revised minimum annual volume hereinafter agreed to by the parties, then Patheon shall be entitled
to request an adjustment to the fee for Manufacturing Services in respect of that Product to reflect the increased costs that Patheon will incur as a result of the reduced volumes;

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

5

 

	(b)
	Component
Costs. If at any time market conditions result in Patheon's cost of Components being greater than normal forecasted increases, then Patheon shall be entitled to request an
adjustment to the fee for Manufacturing Services in respect of any affected Product to compensate it for such increased Component costs. For the purposes of this Section 4.2(b), changes greater
than normal forecasted increases shall be considered to have occurred if (i) the cost of a Component is more than [**] greater than the cost for that Component upon
which the fee quote was based or (ii) the aggregate cost for all Components required to manufacture a Product is more than [**]of the total Component costs for such
Product upon which the fee quote was based. To the extent that Manufacturing Services fees have been previously adjusted pursuant to this Section 4.2(b) to reflect an increase in the cost of
one or more Components, the adjustments provided for in (i) and (ii) above shall operate based on the costs attributed to such Component (or Components) at the time the last of such
adjustments were made;In connection with a fee adjustment request pursuant to this Section 4.2, Patheon shall deliver to Cephalon a revised Schedule A and such budgetary pricing
information, adjusted Component costs or other documentation sufficient to demonstrate that a fee adjustment is justified. Upon delivery of such a request, each of Cephalon and Patheon shall forthwith
use all reasonable efforts to agree on a revised fee for the Manufacturing Services in respect of each affected Product. 

4.3   Adjustments to Subsequent Year's Pricing. 

        The
fees for the Manufacturing Services provided pursuant to the terms of this Agreement during any period following the first anniversary of this Agreement shall be determined in
accordance with the following: 

	(a)
	Manufacturing
Costs. On each yearly anniversary of this Agreement, Patheon shall be entitled to request an adjustment to the fees for Component costs and Manufacturing Services fees
in respect of the Products for increase in manufacturing costs based on the increases in the Industrial Product Price Index, Pharmaceuticals, No.
V157093 and the Consumer Price Index, published by Statistics Canada in respect of the immediately prior Year;

	(b)
	Annual
Forecast. At least ninety days prior to the end of the each Year of this Agreement, Cephalon shall provide Patheon a yearly volume projection. To the extent that Patheon
determines that the projections contained in that yearly volume forecast necessitate that an adjustment be made to the fee for Component costs and Manufacturing Services fees in respect of any Product
for such Year, Patheon shall, within thirty days of receipt by Patheon of the yearly forecast, be entitled to request an appropriate price adjustment.

	(c)
	Pricing
Basis. Cephalon acknowledges that the fee for Manufacturing Services in respect of a Product in any Year is quoted based upon the minimum run quantity and estimated annual
volume per Product specified in Schedule A or thereafter specified in the forecast provided pursuant to Section 4.3(b) for the Year and is subject to change if the specified minimum run
quantity and estimated annual volume is not met. For greater certainty, if Patheon and Cephalon agree that the minimum run quantity in respect of a Product shall be reduced whether as a result of a
decrease in estimated annual volume or otherwise and, as a result of such reduction, Patheon's costs relating to such Product increase on a per unit basis, then Patheon shall be entitled to an
increase in the fee for Manufacturing Services in respect of such Product by an amount sufficient to absorb such increase. 

        In
connection with a fee adjustment request pursuant to this Section 4.3, Patheon shall deliver to Cephalon a revised Schedule A and such budgetary pricing information,
adjusted Component costs or other documentation sufficient to demonstrate that a fee adjustment is justified. Upon delivery of such a request, each of Cephalon and Patheon shall forthwith use all
reasonable efforts to agree on a revised fee for the Manufacturing Services in respect of each affected Product. 

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

6

  

4.4   Adjustments Due to Technical Changes. 

        Amendments
to Cephalon's Technical Information or the Technical Agreement requested by Cephalon will only be implemented following a technical and cost review by Patheon and are subject
to Cephalon and Patheon reaching agreement as to revisions, if any, to the fees specified in Schedules A or B necessitated by any such amendment. If Cephalon accepts a proposed fee change, the
proposed change in Cephalon's Technical Information shall be implemented, and the fee change shall become effective only with respect to those orders of Products that are manufactured in accordance
with the revised Cephalon's Technical Information. In addition, Cephalon agrees to purchase, at Patheon's cost, all Inventory utilized under the "old" Cephalon's Technical Information and purchased or
maintained by Patheon in order to fill Firm Orders or in accordance with Section 5.3, to the extent that such Inventory can no longer be utilized under the revised Cephalon's Technical
Information. Open purchase orders for Components no longer required under any revised Client's Technical Information that were placed by Patheon with suppliers in order to fill Firm Orders or in
accordance with Section 5.3 shall be cancelled where possible, and where such orders are not subject to cancellation without penalty, shall be assigned to and satisfied by Cephalon. 

	4.5
	Multi-Country Pricing. The pricing set forth in Schedule A of this Agreement is for Product intended for sale and distribution
in the United States of America. If Cephalon decides that it wishes to have Patheon manufacture the Product for countries in addition to the United States of America, the Cephalon shall inform Patheon
of the packaging requirements needed for this new country market and Patheon shall prepare a quotation for consideration by Cephalon of the additional Component costs, if any, packaging fees and the
change over fees for the Product destined for the new country market. The agreed additional packaging requirements and related packaging costs and change over fees shall be set out in a written
amendment to this Agreement. 

 
 

ARTICLE 5
  ORDERS, DELIVERY, INVOICING, PAYMENT, PRODUCT DEFICIENCIES    
    

5.1   Market Outlook. 

        Cephalon
acknowledges that for optimal production planning, Patheon requires an understanding of Cephalon's strategic vision for the Products in the market and agrees, to the extent that
such information (including, if any, Cephalon's five-year market outlook studies) exists, to share such information with Patheon, provided that such information may not be relied upon by
Patheon for any purpose and further provided that any information so provided shall be subject to the confidentiality provisions of Article 10. 

5.2   Orders and Forecasts. 

        Cephalon
shall provide Patheon with the following: 

	(a)
	concurrent
with the execution of this Agreement, a written non-binding twelve (12) month forecast of the volume of each Product that Cephalon then anticipates will
be required to be produced and delivered to Cephalon during that twelve (12) month period. Such forecast will be updated by Cephalon monthly on a rolling twelve (12) month basis and
updated forthwith upon Cephalon determining that the volumes contemplated in the most recent of such forecasts has changed by more than twenty per cent; and

	(b)
	on
or before the 20th day of each month, firm written orders ("Firm Orders") for the Products to be produced and delivered to Cephalon
on a date not less than 12 weeks from the date that the Firm Order is submitted. Such Firm Orders submitted to Patheon shall specify Cephalon's purchase order number, quantities by Product type,
monthly delivery schedule and 

7

 

any
other elements necessary to ensure the timely production and delivery of the Products. The quantities of Products ordered in such written orders shall be firm and binding on Cephalon and shall not
be subject to reduction. 

	(c)
	on
or before September 30 in each Year, a written non-binding three-year forecast (broken down by quarters for the second and third years of the
forecast) of the volume of each Product Cephalon then anticipates will be required to be produced and delivered to Cephalon during the three-year period. 

5.3   Reliance by Patheon. 

        Cephalon
understands and acknowledges that Patheon will rely on the Firm Orders submitted pursuant to Section 5.2(b) in ordering the Components required to meet such Firm Orders.
In addition, Cephalon understands that to ensure an orderly supply of such Components and to achieve economies of scale in the costs therefor, it may be desirable for Patheon to purchase such
Components in sufficient volumes to meet the production requirements for Products during part or all of the forecasted periods referred to in Section 5.2(a) or to meet the production
requirements of any longer period agreed to by Patheon and Cephalon. Accordingly, Cephalon authorizes Patheon to purchase Components in order to satisfy the production requirements for Products for
the first six months contemplated in the most recent forecast provided by Cephalon pursuant to Section 5.2(a), and agrees that Patheon may make such other purchases of Components to meet
production requirements during such longer periods as may be agreed to in writing from time to time by Cephalon at the request of Patheon. If Components ordered by Patheon pursuant to Firm Orders or
this Section 5.3 are not included in finished Products purchased by Cephalon within six months after the forecasted month in respect of which such purchases have been made (or such longer
period as the parties may agree), Cephalon shall pay to Patheon its costs thereof and, in the event such Components are incorporated into Products subsequently purchased by Cephalon, Cephalon will
receive credit for any costs of such Components previously paid to Patheon by Cephalon. 

5.4   Minimum Orders. 

        Cephalon
may only order Products in multiples of the minimum run quantities set out in Schedule A. 

5.5   Shipments. 

        Shipments
of Products shall be made FCA Patheon's shipping point. Such title as Patheon has in Products and risk of loss or of damage to Products shall remain with Patheon until Products
are delivered to the carrier by Patheon for shipment at the FCA point at which time title and risk of loss or damage shall transfer to Cephalon. Patheon shall, in accordance with Cephalon's
instructions and as agent for Cephalon, (i) arrange for shipping and insurance, including preparing and executing a packing list, Dangerous Goods Declaration and MSDS, with freight and
insurance to be paid by Cephalon and (ii) at Cephalon's risk and expense, obtain any export licence or other official authorization and carry out all customs formalities necessary to export the
Products. Cephalon may select the freight carrier used by Patheon to ship Products and may monitor Patheon's shipping and freight practices as they pertain to this Agreement. Products shall be
transported in accordance with Cephalon's Technical Information. 

5.6   Invoices and Payment. 

        Except
as otherwise provided in this Agreement, Patheon shall charge Cephalon for the Manufacturing Services only in respect of those Products that are shipped to Cephalon and shall
submit to Cephalon, with each shipment of Products, an invoice covering such shipment. Patheon shall also 

8

 

provide
Cephalon with an invoice covering any Inventory or Components which are to be purchased by Cephalon pursuant to the terms of this Agreement. Each such invoice shall, to the extent applicable,
identify Cephalon purchase order number, Product numbers, names and quantities, unit price, freight charges and the total amount to be remitted by Cephalon. Cephalon shall pay all such invoices within
thirty days of the receipt thereof. 

5.7   Product Deficiencies. 

	(a)
	Inspection.
Cephalon shall inspect the Products manufactured by Patheon upon receipt thereof and, within 30 days of receipt of the Products and the certificates of analysis,
and shall give Patheon written notice (a "Deficiency Notice") of all claims for Products that deviate from Patheon's Manufacturing Responsibilites.
Latent defects shall be reported to Patheon within ten (10) days after Cephalon's discovery of same. Should Cephalon fail to provide Patheon with written notice of its acceptance or rejection
of the delivery within the time periods specified above, then the delivery shall be deemed to have been accepted by Cephalon. Except as set out in Section 6.2, Patheon shall have no liability
for any deviations for which it has not received notice within the periods specified above.

	(b)
	Determination
of Deficiency. Upon receipt of a Deficiency Notice, Patheon shall have 10 days to advise Cephalon by notice in writing that it disagrees with the contents of such
Deficiency Notice. If Cephalon and Patheon fail to agree within 10 days after Patheon's notice to Cephalon as to whether any Products identified in the Deficiency Notice deviate from Cephalon's
Technical Information or cGMPs, or the Technical Agreement, then the parties shall mutually select an independent laboratory to evaluate if the Products deviate from Cephalon's Technical Information
or cGMPs or the Technical Agreement. Such evaluation shall be binding on the parties, and if such evaluation certifies that any Products deviate from Patheon's Manufacturing Responsibilities, Cephalon
may reject those Products in the manner contemplated by Section 5.7(c). If such evaluation does not so certify in respect of any such Products, then Cephalon shall be deemed to have accepted
delivery of such Products on the fortieth day after delivery.

	(c)
	Product
Rejection. Subject to the provisions of Sections 5.7(a) and 9.2(b), Cephalon has the right to reject and return, at the expense of Patheon, any portion of any shipment of
Products that deviates from Cephalon's Technical Information or cGMPs, without invalidating any remainder of such shipment, to the extent that such deviation arises from Patheon's failure to provide
the Manufacturing Services in accordance with the Patheon Manufacturing Responsibilities. 

 
 

ARTICLE 6
  CO-OPERATION    
    

6.1   Quarterly Review. 

        Each
party shall forthwith upon execution of this Agreement appoint one of its employees to be a relationship manager responsible for liaison between the parties. The relationship
managers shall meet not less than quarterly to review the current status of the business relationship and manage any issues that have arisen. 

6.2   Product Recalls and Returns. 

	(a)
	Product
Recalls. Patheon and Cephalon shall each maintain records as may be necessary to permit a recall or a field correction of any Products delivered to Cephalon or customers of
Cephalon, effected voluntarily or under a threat of, or a directive by, any governmental 

9

 

agency.
Each party shall give notice within one Business Day by telephone (to be confirmed in writing) to the Director of Quality Control/Quality Assurance of the other party upon discovery that any
Products should be recalled or corrected, or may be required to be recalled or corrected, and each party upon receiving any such notice or upon any such discovery, shall cease and desist from further
shipments of such Products in its possession or control until a decision has been made whether a recall or some other corrective action is necessary. The decision to initiate a recall or to take some
other corrective action, if any, shall be made and implemented by Cephalon. Patheon will co-operate as reasonably required by Cephalon, having regard to all applicable laws and
regulations. 

	(b)
	Product
Returns. Cephalon shall have the responsibility for handling customer returns of the Products. Patheon shall provide Cephalon with such assistance as Cephalon may reasonably
need to handle such returns.

	(c)
	Patheon's
Responsibility. To the extent that a recall or return results from, or arises out of, a failure by Patheon to provide the Manufacturing Services in accordance with the
Patheon Manufacturing Responsibilities, such recall or return shall be made at Patheon's cost and expense, and Patheon shall use its best efforts to replace the recalled or returned Products with new
Products within 60 days from the date that Cephalon definitively notifies Patheon about the recalled or returned Products, contingent upon the receipt or availability from Cephalon of all
Active Materials. Patheon's cost for such Active Materials shall be limited to the Active Materials Value thereof. In the event that Patheon is unable to replace the recalled Products within this
60-day period (except where such inability results from a failure to receive the required Active Materials), then Cephalon may request Patheon to reimburse Cephalon for the price that
Cephalon paid to Patheon for manufacturing the affected Products. In all other circumstances, recalls, returns or other corrective actions shall be made at Cephalon's cost and expense. 

6.3   Customer Questions and Complaints. 

        Cephalon
shall have the sole responsibility for responding to questions and complaints and Adverse Experiences from Cephalon's customers. Questions or complaints or Adverse Experiences
received by Patheon from Cephalon's customers shall be referred to Cephalon within two (2) business days of receipt. Patheon shall co-operate as reasonably required to allow
Cephalon to determine the cause of and resolve any customer questions and complaints and Adverse Experiences. Such
assistance shall include follow-up investigations, including testing. In addition, within 10 days from the date of request, Patheon shall provide Cephalon with all necessary
information that will enable Cephalon to respond properly to questions or complaints or Adverse Experiences relating to the Products. Unless it is determined that the cause of any customer complaint
or Adverse Experiences resulted from a failure by Patheon to provide the Manufacturing Services in accordance with the Patheon Manufacturing Responsibilities, all costs incurred in respect of this
Section 6.3 shall be borne by Cephalon. 

6.4   Governmental Agencies. 

        Cephalon
shall be primarily responsible for communicating with any governmental agency, including but not limited to governmental agencies responsible for granting regulatory approval
for the Products, regarding such Products; provided, however, that if in the opinion of Patheon's counsel, it must communicate with a governmental agency to comply with the terms of this Agreement or
the requirements of any law, governmental order or regulation it may do so. Unless, in the reasonable opinion of its counsel, there is a legal prohibition against doing so, each party shall permit the
other party to accompany and take part in any communications with the agency, and to receive copies of all such communications from the agency. 

10

 

6.5   Records and Accounting by Patheon. 

        Patheon
shall keep records of the manufacture, testing and shipping of the Products, the Active Materials and Components, and retain samples of such Products, Active Materials and
Components as are necessary to comply with manufacturing regulatory requirements applicable to Patheon, as well as to assist with resolving product complaints and other similar investigations. Copies
of such records and samples shall be retained for a period of five years following the date of manufacture, or longer if required by law. Cephalon is responsible for retaining samples of the Products
necessary to comply with the legal/regulatory requirements applicable to Cephalon. 

6.6   Inspection. 

        Cephalon
may inspect Patheon reports and records relating to this Agreement during normal business hours and with reasonable advance notice, provided a Patheon representative is present
during any such inspection. Patheon shall promptly notify Cephalon of any contacts, inspections or audits by any
governmental agency involving the Products. Patheon will promptly provide Cephalon with copies of any government-issued inspection observation reports (including without limitation FDA
Form 483s and equivalent forms from other regulatory bodies) and agency correspondence, purged only of confidential information that is unrelated to the Products, that may be reasonably
expected to adversely affect the Products. Patheon and Cephalon will cooperate in resolving any concerns with any governmental agency. Patheon will also inform Cephalon of any action taken by any
governmental agency against Patheon or any of its officers or employees which may be reasonably expected to adversely affect the Products or Patheon's ability to supply the Products hereunder within
24 hours after the action is taken. 

6.7   Access. 

        Patheon
shall provide Cephalon with reasonable access at mutually agreeable times to any of its facilities in which the Products are manufactured, stored, handled or shipped in order to
permit Cephalon's verification of Patheon's compliance with the terms of this Agreement and with all applicable laws and regulations. 

6.8   Reports. 

        Patheon
will supply on an annual basis all product data, including release test results, complaint test results, all investigations (in manufacturing, testing and storage), and the like,
that Cephalon reasonably requires in order to complete any filing under any applicable regulatory regime, including any Annual Product Review report that Cephalon is required to file with the FDA. 

6.9   Validation. 

        Patheon
will at Cephalon's expense validate all processes, methods, equipment, utilities, facilities and computers used in the formulation, packaging, storage, testing and release of
Products in conformance with all applicable laws and regulations. Cephalon will have the right to review the results of said validation upon request. 

6.10 Quality Compliance. 

        Patheon
will provide Cephalon with timely notification of all significant deviations, notes to file, and other deficiencies that may be reasonably expected to impact the quality of the
Products, as well as all FDA reports regarding testing, manufacture, packaging or labelling of the Products. 

11

 

6.11 Batch Records. 

        Patheon
will prepare records which include information relating to the manufacturing, packaging and quality operations for each lot of Products at the time such operations occur. Patheon
will prepare such records in accordance with cGMPs and the Technical Agreement. 

 
 

ARTICLE 7
  TERM AND TERMINATION    
    

7.1   Initial Term. 

        This
Agreement shall become effective as of the Commencement Date and shall continue for a period of five years from such date (the "Initial
Term"), unless terminated earlier by one of the parties as provided herein. This Agreement shall automatically continue after the Initial Term for successive terms of one year
each unless either party gives not less than eighteen (18) months prior written notice to the other party of its intention to terminate this Agreement. 

7.2   Termination for Cause. 

	(a)
	Either
party at its sole option may terminate this Agreement upon written notice in circumstances where the other party has failed to remedy a material breach of any of its
representations, warranties or other obligations under this Agreement within 60 days following receipt of a written notice (the "Remediation
Period") of said breach that expressly states that it is a notice under this Section 7.2(a) (a "Breach Notice"). The
aggrieved party's right to terminate this Agreement pursuant to this Section 7.2(a) may only be exercised for a period of 60 days following the expiry of the Remediation Period (in
circumstances where the breach has not been remedied) and if the termination right is not exercised during this period then the aggrieved party shall be deemed to have waived the breach of the
representation, warranty or obligation described in the Breach Notice.

	(b)
	Either
party at its sole option may immediately terminate this Agreement upon written notice, but without prior advance notice, to the other party in the event that (i) the
other party is declared insolvent or bankrupt by a court of competent jurisdiction; (ii) a voluntary petition of bankruptcy is filed in any court of competent jurisdiction by such other party;
or (iii) this Agreement is assigned by such other party for the benefit of creditors.

	(c)
	Cephalon
may terminate this Agreement as to any Product upon 30 days' written notice in the event that any governmental agency takes any action, or raises any objection, that
prevents Cephalon from importing, exporting, purchasing or selling such Product.

	(d)
	Patheon
may terminate this Agreement on six months' prior written notice if Cephalon assigns pursuant to Section 12.5 any of its rights under this Agreement to an assignee
that, in the opinion of Patheon acting reasonably, is (i) not a credit worthy substitute for Cephalon, (ii) a competitor of Patheon or (iii) a person with whom Patheon has had
prior unsatisfactory business relations. 

7.3   Product Discontinuation. 

        Cephalon
shall provide at least six months' advance notice if it intends to no longer order a Product due to that Product's discontinuance in the market. 

12

 

7.4   Obligations on Termination. 

        If
this Agreement expires or is terminated in whole or in part for any reason, then (in addition to any other remedies either party may have in the event of default by the other party): 

	(a)
	Cephalon
shall take delivery of and pay for all undelivered Products that are manufactured and/or packaged pursuant to a Firm Order, at the price in effect at the time the Firm Order
was placed;

	(b)
	Cephalon
shall purchase, at Patheon's cost, the Inventory applicable to the Products which was purchased, produced or maintained by Patheon in contemplation of filling Firm Orders or
in accordance with Section 5.3 prior to notice of termination being given;

	(c)
	Cephalon
shall satisfy the purchase price payable pursuant to Patheon's orders with suppliers of Components, provided such orders were made by Patheon in reliance on Firm Orders or in
accordance with Section 5.3; and

	(d)
	Patheon
shall return to Cephalon all unused Active Materials (with shipping and related expenses, if any, to be done by Cephalon). 

        Any
termination or expiration of this Agreement shall not affect any outstanding obligations or payments due hereunder prior to such termination or expiration, nor shall it prejudice any
other remedies that the parties may have under this Agreement. For greater certainty, termination of this Agreement for any reason shall not affect the obligations and responsibilities of the parties
pursuant to Article 9, all of which survive any termination. 

 
 

ARTICLE 8
  REPRESENTATIONS, WARRANTIES AND COVENANTS    
    

8.1   Authority. 

        Each
party represents and warrants that it has the full right and authority to enter into this Agreement, and that it is not aware of any impediment that would inhibit its ability to
perform its obligations hereunder. 

13

  

8.2   General. 

        Patheon
represents and warrants to Cephalon that (a) it has and will maintain throughout the pendency of this Agreement, the expertise, with respect to personnel and equipment, to
fulfill the obligations established hereunder, and has obtained all requisite material licenses, authorizations and approvals required by federal, provincial or local government authorities including,
but not limited to, the FDA, Environmental Protection Agency ("EPA"), Ontario Health and Safety Act ("OHSA"), etc. to manufacture the Products; (b) the production facility, equipment and
personnel to be employed to formulate and package the Products will be qualified to manufacture product in accordance with cGMPs at the time each such batch of Products is produced, and that the
production facilities to be employed is in compliance with all applicable material laws and regulations; (c) there are no pending or uncorrected citations or adverse conditions noted in any
inspection of the production facilities to be employed which would cause the Products to be misbranded or adulterated within the meaning of the United States Food, Drug and
Cosmetics Act of 1938 (21 U.S.C. Section 201 et seq.), together with any regulation promulgated thereunder, including without limitation, all cGMPs, in each case as
amended from time to time. 

8.3   Non-Infringement. 

        Cephalon
represents and warrants that: 

	(a)
	Cephalon's
Technical Information for each of the Products is owned or licensed by it or an Affiliate and that Cephalon may lawfully disclose Cephalon's Technical Information to
Patheon;

	(b)
	any
Intellectual Property included in Cephalon's Technical Information and utilized by Patheon in connection with the provision of the Manufacturing Services (i) is Cephalon's
or its Affiliate's unencumbered property, (ii) may be lawfully used as directed by Cephalon, and (iii) such use does not infringe any Third Party Rights;

	(c)
	the
provision of the Manufacturing Services by Patheon in respect of any Product pursuant to this Agreement or use or other disposition of any Product by Patheon as may be required to
perform its obligations under this Agreement does not and will not infringe any Third Party Rights;

	(d)
	there
are no actions or other legal proceedings, the subject of which is the infringement of Third Party Rights related to any of Cephalon's Technical Information, or any of the
Active Materials and the Components, or the sale, use or other disposition of any Product made in accordance with Cephalon's Technical Information;

	(e)
	Cephalon's
Technical Information for all Products conforms to all applicable cGMPs, laws and regulations; and

	(f)
	the
Products, if labelled and manufactured in accordance with Cephalon's Technical Information and in compliance with applicable cGMPs (i) may be lawfully sold and distributed
in every jurisdiction in which Cephalon markets such Products, (ii) will be fit for the purpose intended, and (iii) will be safe for human consumption. 

8.4   Debarred Persons. 

        Patheon
covenants that it will not in the performance of its obligations under this contract use the services of any person debarred or suspended under 21 U.S.C. §335(a) or
(b). Patheon represents that it does not currently have, and covenants that it will not hire, as an officer or an employee any person who has been convicted of a felony under the laws of the United
States for conduct relating to the regulation of any drug product under the United States Food, Drug and Cosmetic Act. 

14

 

8.5   Permits. 

        Cephalon
shall be solely responsible for obtaining or maintaining any permits or other regulatory approvals in respect of the Products or Cephalon's Technical Information, including,
without limitation, all marketing and post-marketing approvals. Patheon shall be responsible for obtaining and maintaining all site license for the manufacture of Products and shall comply
with all applicable regulations promulgated by the FDA in connection with the manufacture of Products. 

8.6   Compliance with Laws. 

        Each
party, in connection with its performance under this Agreement, shall comply with all applicable laws, rules, regulations, orders and guidelines. 

 
 

ARTICLE 9
  REMEDIES AND INDEMNITIES    
    

9.1   Consequential Damages. 

        Under
no circumstances whatsoever shall either party be liable to the other in contract, tort, negligence, breach of statutory duty or otherwise for any (direct or indirect) loss of
profits, of production, of anticipated savings, of business or goodwill or for any liability, damage, costs or expense of any kind incurred by the other party of an indirect or consequential nature. 

9.2   Limitation of Liability. 

	(a)
	Active
Materials. Patheon shall not be responsible for any loss or damage to the Active Materials, except where such loss or damage occurs while such materials are located on
Patheon's premises and results from a failure by Patheon to provide the Manufacturing Services in accordance with the Patheon Manufacturing Responsibilities or is otherwise due to Patheon's negligence
or intentional misconduct. In such circumstances, Patheon's liability shall be limited to the Active Materials Value attributable to the relevant Active Materials lost or damaged provided that
(i) Patheon shall not be required to pay more that [**] per batch and (ii) Patheon's annual maximum liability for the replacement costs of Active Materials for
such Product shall be [**] in any one Year. For greater certainty, Cephalon acknowledges that loss or damage of Active Materials in the course of technology transfer, or as
part of failed regulatory, stability or test batches, shall not be regarded as lost due to the negligence or intentional misconduct of Patheon unless and to the extent that Patheon did not provide the
Manufacturing Services in accordance with cGMPs.

	(b)
	Products.
Except in circumstances where Patheon has failed to provide the Manufacturing Services in accordance with the Patheon Manufacturing Responsibilities, Patheon shall not be
liable nor have any responsibility for any deficiencies in, or other liabilities associated with, any Product manufactured by it, including, without limitation, any deficiencies with respect to
Cephalon's Technical Information, the safety, efficacy or marketability of the Products or any distribution risk. Except as set out in Section 6.2(c), if Patheon has failed to provide the
Manufacturing Services in accordance with the Patheon Manufacturing Responsibilities, then Cephalon shall have no obligation to pay for such Products. In addition, Patheon shall, at its sole cost and
expense and in full and final satisfaction of all claims Cephalon may have in respect of the deficient Products, manufacture additional Products to replace such deficient Products, provided that
Cephalon shall supply Patheon with the additional Active Materials that are needed to manufacture the Products for a cost to Patheon equal to the Active Materials Value of such Active Materials
provided that (i) Patheon shall not be required to pay more that [**] per batch and (ii) Patheon's annual maximum liability for the replacement costs of Active
Materials for such Product shall be [**] in any one Year.

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

15

 

9.3   Patheon. 

        Subject
to Section 9.1 and 9.2, Patheon agrees to defend, indemnify and hold Cephalon, its officers, employees and agents harmless against any and all losses, damages, costs,
claims, demands, judgments and liability to, from and in favour of third parties (other than Affiliates) resulting from, or relating to any claim of personal injury or property damage to the extent
that such injury or damage is the result of a failure by Patheon to provide the Manufacturing Services in accordance with the Patheon Manufacturing Responsibilities or any breach of this Agreement by
Patheon, including, without limitation, any representation or warranty contained herein, except to the extent that any such losses, damages, costs, claims, demands, judgments and liability are due to
the negligence or wrongful act(s) of Cephalon, its officers, employees or agents. Cephalon shall promptly notify Patheon of any such claim, shall use commercially reasonable efforts to mitigate the
effects of such claim, shall reasonably cooperate with Patheon in the defense of such claim and shall permit Patheon to control the defense and settlement of such claim, all at Patheon's cost and
expense. 

9.4   Cephalon. 

        Subject
to 9.1 and 9.2, Cephalon agrees to defend, indemnify and hold Patheon, its officers, employees and agents harmless against any and all losses, damages, costs, claims, demands,
judgments and liability to, from and in favour of third parties (other than Affiliates) resulting from, or relating to any claim of infringement or alleged infringement of any Third Party Rights in
respect of the Products, and any claim of personal injury or property damage to the extent that such injury or damage is the result of a breach of this Agreement by Cephalon, including, without
limitation, any representation or warranty contained herein, except to the extent that any such losses, damages, costs, claims, demands, judgments and liability are due to the negligence or wrongful
act(s) of Patheon, its officers, employees or agents. Patheon shall promptly notify Cephalon of any such claims, shall use commercially reasonable efforts to mitigate the effects of such claim, shall
reasonably cooperate with Cephalon in the defense of such claims and shall permit Cephalon to control the defense and settlement of such claims, all at Cephalon's cost and expense. 

9.5   Reasonable Allocation of Risk. 

        The
parties acknowledge and agree that the provisions of this Agreement (including, without limitation, this Article 9) are reasonable and create a reasonable allocation of risk
having regard to the relative profits the parties respectively expect to derive from the Products, and that Patheon, in its fees for the provision of the Manufacturing Services, has not accepted a
greater degree of the risks arising from the manufacture, distribution and use of the Products, based on the fact that Cephalon has developed and holds the marketing approval for the Products and
requires Patheon to manufacture and label the Products strictly in accordance with Cephalon's Technical Information, and that Cephalon and not Patheon is in a position to inform and advise potential
users of the Products as to the circumstances and manner of use of the Products. 

 
 

ARTICLE 10
  CONFIDENTIALITY    
    

10.1 Disclosure  

        During and in furtherance of this Agreement, each of the parties hereto may disclose certain of its Confidential Information to the other party. 

10.2 Use of Information  

        During the Initial Term and any renewals of this Agreement, and for a period of five years from the termination of this Agreement, each of the parties hereto
agrees (i) to use the Confidential 

16

 

Information
only in connection with the terms of this Agreement; (ii) to treat the Confidential Information as it would its own proprietary information; and (iii) to take all reasonable
precautions to prevent the disclosure of the Confidential Information to any third party, other than an Affiliate, without the prior written consent of the other party.. 

10.3 Exceptions  

        Each of Patheon and Cephalon shall be relieved of any and all of the obligations under Section 10.2 regarding Confidential Information which (i) was
known by the recipient prior to receipt hereunder; (ii) at the time of disclosure, was generally available to the public, or which after disclosure hereunder becomes generally available to the
public through no fault attributable to a party hereto; or (iii) is hereafter made available for use or disclosure from any third party having a right to do so. 

10.4 Designation of Confidentiality. 

        All
oral information shall be reduced to writing forthwith after disclosure. Each party shall either mark its Confidential Information "Confidential" or "Proprietary" or ensure that it
is covered by a notice indicating that such information is confidential. For greater certainty, a verbal disclosure by a party of its Confidential Information shall be followed by a written Summary of
the conversation marked "Confidential" and be delivered to the other party within thirty days of the conversation. 

 
 

ARTICLE 11
  DISPUTE RESOLUTION    
    

11.1 Commercial Disputes. 

        In
the event of any dispute arising out of or in connection with this Agreement (other than a dispute determined in accordance with Section 5.7(b) or a Technical Dispute), the
parties shall first try to solve it amicably. In this regard, any party may send a notice of dispute to the other, and each party shall appoint, within 10 Business Days from receipt of such notice of
dispute, a single representative having full power and authority to solve the dispute. The representatives so designated shall meet as necessary in order to solve such dispute. If these
representatives fail to solve the matter within one month from their appointment, or if a party fails to appoint a representative within the 10 Business Day period set forth above, such dispute shall
immediately be referred to the Chief Operating Officer or Executive Vice President, Operations (or such other officer as they may designate) of each party who will meet and discuss as necessary in
order to try to solve the dispute amicably. Should the parties fail to reach a resolution under this Section 11.1, their dispute will be referred to a court of competent jurisdiction in
accordance with Section 12.12. 

11.2 Technical Dispute Resolution. 

        In
the event of a dispute (other than disputes in relation to the matters set out in Sections 5.7(b) and 11.1) between the parties that is exclusively related to technical aspects of the
manufacturing, packaging, labelling, quality control testing, handling, storage or other activities under this Agreement (a "Technical Dispute"), the
parties shall make all reasonable efforts to resolve the dispute by amicable negotiations. In this regard, senior representatives of each party shall, as soon as practicable and in any event no later
than 10 Business Days after a written request from either party to the other, meet in good faith to resolve any Technical Dispute. If, despite such meeting, the parties are unable to resolve a
Technical Dispute within a reasonable time, and in any event within 30 Business Days of such written request, the Technical Dispute shall, at the request of either party, be referred for determination
to an expert in accordance with the provisions of Schedule F. In the event that the parties cannot agree whether a dispute is a Technical Dispute, Section 11.1 shall prevail. For greater
certainty, the parties 

17

 

agree
that the release of the Products for sale or distribution pursuant to the applicable marketing approval for such Products shall not by itself indicate compliance by Patheon with its obligations
in respect of the Manufacturing Services and further that nothing in this Agreement (including Schedule F) shall remove or limit the authority of the relevant qualified person (as specified by
the Technical Agreement) to determine whether the Products are to be released for sale or distribution. 

 
 

ARTICLE 12
  TRADEMARKS    
    

12.1 Trademarks. 

        Patheon
shall have the non-exclusive right to use the Trademarks in packaging the Products in connection with fulfilling its obligations hereunder. The rights granted Patheon
hereunder to use the Trademarks shall in no way affect Cephalon's ownership of such Trademarks. No other right, title or interest in the Trademarks is established hereby, and nothing herein shall be
construed to grant any right or license to Patheon to use the Trademarks or the name CEPHALON, other than as specifically set forth herein. Patheon will manufacture and package the Products using only
the relevant Trademarks listed in Schedule H. Patheon will use the Trademarks in strict accordance with instructions given by Cephalon and shall not make any changes to the Trademarks. Upon
termination of this Agreement, Patheon will cease all use of the Trademarks and any license to use the Trademarks granted hereunder shall be cancelled. 

 
 

ARTICLE 13
  MISCELLANEOUS    
    

13.1 Intellectual Property. 

        Cephalon
and Patheon hereby acknowledge that neither party has, nor shall it acquire, any interest in any of the other party's Intellectual Property unless otherwise expressly agreed to
in writing. Each party agrees not to use any Intellectual Property of the other party, except as specifically authorized by the other party or as required for the performance of its obligations under
this Agreement. Any inventions, discoveries, improvements, or trade secrets made by Patheon in the performance of this Agreement that specifically relate to the Products or their manufacture
(including any new use or any change in the method of producing testing or storing the Products) shall be owned by Cephalon. Patheon shall execute such instruments as shall be required to evidence or
effectuate Cephalon's ownership of any such inventions, and shall cooperate upon reasonable request (and at Cephalon's expense) in the prosecution of patents and other intellectual property rights
related to any such inventions. 

13.2 Insurance. 

        Each
party shall maintain commercial general liability insurance, including blanket contractual liability insurance covering the obligations of that party under this Agreement through
the term of this Agreement and for five years thereafter, which insurance shall afford limits of not less than $5,000,000 for each occurrence for personal injury liability, products liability and
property damage liability. If requested each party will provide the other with a certificate of insurance evidencing the above and showing the name of the issuing company, the policy number, the
effective date, the expiration date and the limits of liability. The insurance certificate shall further provide for a minimum of thirty days' written notice to the insured of a cancellation of, or
material change in, the insurance. 

18

 

13.3 Independent Contractors. 

        The
parties are independent contractors and this Agreement shall not be construed to create between Patheon and Cephalon any other relationship such as, by way of example only, that of
employer-employee, principal agent, joint-venturer, co-partners or any similar relationship, the existence of which is expressly denied by the parties hereto. 

13.4 No Waiver. 

        Either
party's failure to require the other party to comply with any provision of this Agreement shall not be deemed a waiver of such provision or any other provision of this Agreement. 

13.5 Assignment. 

        Patheon
may not assign this Agreement or any of its rights or obligations hereunder except with the written consent of Cephalon, such consent not to be unreasonably withheld. For greater
certainty, Patheon may arrange for subcontractors to perform specific services arising under this Agreement provided that Patheon remains responsible to Cephalon under this Agreement. Subject to
Section 7.2(d), Cephalon may assign this Agreement or any of its rights or obligations hereunder without approval from Patheon; provided, however, that Cephalon shall give prior written notice
of any assignment to Patheon, any assignee shall covenant in writing with Patheon to be bound by the terms of this Agreement and Cephalon shall remain liable hereunder. Notwithstanding the foregoing
provisions of this Section 13.5 or the provisions of Section 7.2(d), either party may assign this Agreement to any of its Affiliates or to a successor to or purchaser of all or
substantially all of its business, provided that such assignee executes an agreement with the non-assigning party hereto whereby it agrees to be bound hereunder. 

13.6 Force Majeure. 

        Neither
party shall be liable for the failure to perform its obligations under this Agreement if such failure is occasioned by a cause or contingency beyond such party's reasonable
control, including, but not limited to, strikes or other labour disturbances, lockouts, riots, wars, fires, floods, storms, interruption of or delay in transportation, or compliance with any order or
regulation of any government entity acting within colour of right. A party claiming a right to excused performance under this Section 12.6 shall immediately notify the other party in writing of
the extent of its inability to perform, which notice shall specify the occurrence beyond its reasonable control that prevents such performance. 

13.7 Additional Product. 

        Additional
products may be added to this Agreement and such additional products shall be governed by the general conditions hereof with any special terms (including, without limitation,
price) governed by an addendum hereto. 

13.8 Notices. 

        Any
notice, approval, instruction or other written communication required or permitted hereunder shall be sufficient if made or given to the other party by personal delivery, by
telecopier or facsimile 

19

 

communication
or by sending the same by first class mail, postage prepaid to the mailing address, or telecopier or facsimile number set forth below: 

	 	 	If to Cephalon:
	

 	
 	

Cephalon, Inc.

145 Brandywine Parkway

West Chester, PA 19380-4245
	

 	
 	

Attention: Robert J. Urban, Vice President, Technical Operations
	

 	
 	

Telecopier No.: 610-738-6315
	

 	
 	

If to Patheon:

Patheon Inc.

2100 Syntex Court

Mississauga, Ontario

Canada L5n 7K9
	

 	
 	

Attention: President

Telecopier No.: (905) 812-6705

or
to such other addresses or telecopier or facsimile numbers provided to the other party in accordance with the terms of this Section 12.8. Notices or written communications made or given by
personal delivery or by telecopier or facsimile shall be deemed to have been sufficiently made or given when sent (receipt acknowledged), or if mailed, five days after being deposited in the United
States or Canadian mail, postage prepaid or upon receipt, whichever is sooner. 

13.9 Severability. 

        If
any provision of this Agreement is determined by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such determination shall not impair or
affect the validity, legality or enforceability of the remaining provisions hereof, and each provision is hereby declared to be separate, severable and distinct. 

13.10   Entire Agreement. 

        This
Agreement, together with the Technical Agreement and the Confidentiality Agreement, constitutes the full, complete, final and integrated agreement between the parties hereto
relating to the subject matter hereof and supersedes all previous written or oral negotiations, commitments, agreements, transactions or understandings with respect to the subject matter hereof. Any
modification, amendment or supplement to this Agreement must be in writing and signed by authorized representatives of both parties. In case of conflict, the prevailing order of documents shall be
this Agreement, the Technical Agreement and the Confidentiality Agreement. 

13.11   No Third Party Benefit or Right. 

        For
greater certainty, nothing in this Agreement shall confer or be construed as conferring on any third party any benefit or the right to enforce any express or implied term of this
Agreement. 

13.12   Execution in Counterparts. 

        This
Agreement may be executed in two counterparts, by original or facsimile signature, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 

20

 

13.13   Governing Law. 

        This
Agreement shall be construed and enforced in accordance with the laws of the State of New York without reference to its choice of law rules. 

        IN
WITNESS WHEREOF, the duly authorized representatives of the parties have executed this Agreement as of the date first written above. 

	 	 	PATHEON INC.
	 	 	By:	/s/  NICK DIPIETRO      
 Nick DiPietro
 President and COO
	

 	
 	
CEPHALON, INC.
	 	 	By:	/s/  ROBERT J. URBAN      
 Robert J. Urban
 Vice President, Technical
Operations

21

  

 
 

SCHEDULE A
  
    PRODUCTS, MINIMUM RUN QUANTITY,
  MINIMUM ANNUAL VOLUME AND FEES    
    

Provigil 100 mg Tablet  

	 
	 	100mg tablet

100's bottle

Low Volume
	 	100mg tablet

Bulk

Low Volume
	 	100mg tablet

100's bottle

High Volume
	 	100mg tablet

Bulk

High Volume

	Annual Quantity (Units)	 	[**]	 	[**]	 	[**]	 	[**]
	Run Quantity (Units)	 	[**]	 	[**]	 	[**]	 	[**]
	Price/Unit	 	[**]	 	[**]	 	[**]	 	[**]

Provigil 200mg Tablet  

	 
	 	200mg

100's bottle

Low Volume
	 	200mg tablet

100's bottle

High Volume

	Annual Quantity (Units)	 	[**]	 	[**]
	Run Quantity (Units)	 	[**]	 	[**]
	Price/Unit	 	[**]	 	[**]

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

22

 

Provigil 100 mg Tablet  

	 
	 	100mg tablet

100's bottle

Low Volume
	 	100mg tablet

Bulk

Low Volume
	 	100mg tablet

100's bottle

High Volume
	 	100mg tablet

Bulk

High Volume

	Annual Quantity (Units)	 	[**]	 	[**]	 	[**]	 	[**]
	Run Quantity (Units)	 	[**]	 	[**]	 	[**]	 	[**]
	Price/Unit	 	[**]	 	[**]	 	[**]	 	[**]

Provigil 200mg Tablet  

	 
	 	200mg

100's bottle

Low Volume
	 	200mg tablet

100's bottle

High Volume

	Annual Quantity (Units)	 	[**]	 	[**]
	Run Quantity (Units)	 	[**]	 	[**]
	Price/Unit	 	[**]	 	[**]

Bottles—pricing
is per bottle of 100 tables / Bulk—pricing is per thousand tablets. 

All prices quoted in US Funds. Revised pricing will be incorporated after finalization of the batch size.

[**(1)]

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

	(1)
	The
omited portion consists of 74 pages. 

23

 
 
 

SCHEDULE B
  
    STABILITY TESTING FEES    
    

        Commercial and Product Stability Protocols and associated pricing to be determined between the parties and, upon execution by the duty authorized representatives
of the parties hereto, attached to this schedule B. 

24

 
 
 

SCHEDULE C
  
    ACTIVE MATERIALS    
    

	Active Material
	 	Supplier

	modafinil	 	Orsymonde

Z.I. Mitry Compans

Rue Gay Lussac

77292 Mitry Mory Cedex

FRANCE

25

  

 
 

SCHEDULE D
  
    ACTIVE MATERIALS VALUE    
    

	Active Material
	 	Quantity Supplied
	 	Active Material Value

per Batch
	 	Maximum Active

Material Value

per Year

	modafinil	 	[**]	 	[**]	 	[**]

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

26

 
 
 

SCHEDULE E
  
    BATCH NUMBERING AND EXPIRATION DATES    
    

        Products manufactured at Patheon Inc. will bear lot numbers as described in Patheon SOP OPS1026 and will have expiry dates as described in Patheon SOP
OPS1062. 

        The
expiry period starts when ingredients are blended. 

 
 

SCHEDULE F
  
    TECHNICAL DISPUTE RESOLUTION    
    

        Technical Disputes which cannot be resolved by negotiation as provided in Section 11.2 shall be resolved in the following matter: 

	1.
	Appointment of Expert. Within 10 Business Days after a party requests pursuant to Section 11.2 that an expert be appointed to
resolve a Technical Dispute, the parties shall jointly appoint a mutually acceptable expert with experience and expertise in the subject matter of the dispute. If the parties are unable to so agree
within such 10 Business Day period, or in the event of disclosure of a conflict by an expert pursuant to paragraph 2 hereof which results in the parties not confirming the appointment of such
expert, then an expert (willing to act in that capacity hereunder) shall be appointed by an experienced arbitrator on the roster of ADR Chambers who shall be a retired judge of the Ontario Superior
Court of Justice.

	2.
	Conflicts of Interest. Any person appointed as an expert shall be entitled to act and continue to act as such notwithstanding that at
the time of his appointment or at any time before he gives his determination, he has or may have some interest or duty which conflicts or may conflict with his appointment provided that before
accepting such appointment (or as soon as practicable after he becomes aware of the conflict or potential conflict) he fully discloses any such interest or duty and the parties shall after such
disclosure have confirmed his appointment.

	3.
	Not Arbitrator. No expert shall be deemed to be an arbitrator and the provisions of the Arbitration
Act (Ontario) or of any other applicable statute (foreign or domestic) and the law relating to arbitration shall not apply to any such expert or the expert's determination or
the procedure by which the expert reaches his determination to be made pursuant to this Schedule E.

	4.
	Procedure. Where an expert is appointed:

	(a)
	Timing.
The expert shall be so appointed on condition that (i) he promptly fixes a reasonable time and place for receiving representations, submissions or information from the
parties and that he issues such authorizations to the parties and any relevant third party for the proper conduct of his determination and any hearing and (ii) he renders his decision (with
full reasons) within 15 Business Days (or such other date as the parties and the expert may agree) after receipt of all information requested by him pursuant to paragraph 4(b) hereof.

	(b)
	Disclosure
of Evidence. The parties undertake one to the other to provide to any expert all such evidence and information within their respective possession or control as the expert
may reasonably consider necessary for determining the matter before him which they shall disclose promptly and in any event within five Business Days of a written request from the relevant expert to
do so.

	(c)
	Advisors.
Each party may appoint such counsel, consultants and advisors as it feels appropriate to assist the expert in his determination and so as to present their respective cases
so that at all times the parties shall co-operate and seek to narrow and limit the issues to be determined. 

27

 

	(d)
	Appointment
of New Expert. If within the time specified in paragraph 4(a) above the expert shall not have rendered a decision in accordance with his appointment, a new expert
may (at the request of either party) be appointed and the appointment of the existing expert shall thereupon cease for the purposes of determining the matter at issue between the parties save that if
the existing expert renders his decision with full reasons prior to the appointment of the new expert, then such a decision shall have effect and the proposed appointment of the new expert shall be
withdrawn.

	(e)
	Final
and Binding. The determination of the expert shall, save in the event of fraud or manifest error, be final and binding upon the parties.

	(f)
	Costs.
Each party shall bear its own costs in connection with any matter referred to an expert hereunder and, in the absence of express provision in the Agreement to the contrary, the
costs and expenses of the expert shall be shared equally by the parties. 

        For
greater certainty, the parties agree that the release of the Products for sale or distribution pursuant to the applicable marketing approval for such Products shall not by itself
indicate compliance by Patheon with its obligations in respect of the Manufacturing Services and further that nothing in this Agreement (including this Schedule F) shall remove or limit the
authority of the relevant qualified person (as specified by the Technical Agreement) to determine whether the Products are to be released for sale or distribution. 

28

  

 
 

SCHEDULE G
  FORM OF TECHNICAL AGREEMENT    
    

        THIS AGREEMENT made as of the 1st day of January, 2003 

B
E T W E E N: 

	

 	
 	

Cephalon, Inc.,

a corporation existing under the laws of the State of Delaware,

(hereinafter referred to as "Cephalon")
	

 	
 	

—and—
	

 	
 	

PATHEON INC.,

a corporation existing under the laws of Canada,

(hereinafter referred to as "Patheon"),

        WHEREAS pursuant to a manufacturing services agreement dated January 1, 2003 between Patheon and Cephalon (the
"MSA"), Patheon agreed to provide pharmaceutical manufacturing services in respect of certain Products (as described in Schedule A hereto); 

        AND
WHEREAS pursuant to the MSA, Cephalon is required to provide certain information to Patheon in order for Patheon to provide the Manufacturing Services (the
"Cephalon's Technical Information"); 

        AND
WHEREAS pursuant to the MSA, Patheon is required to operate within Cephalon's Technical Information as provided; 

        AND
WHEREAS the parties desire to allocate the responsibility for procedures and specifications impacting on the identity, strength, quality and purity of the Products; 

        NOW
THEREFORE in consideration of the rights conferred and the obligations assumed under the MSA and herein, and for other good and valuable consideration (the receipt and sufficiency of
which are acknowledged by each party), and intending to be legally bound the parties agree as follows: 

 
 

ARTICLE 13
  TECHNICAL AGREEMENT    
    

 RESPONSIBILITIES  

	13.1
	Subject
to the terms and conditions hereinafter set out and subject to the terms and conditions of the MSA, the parties agree that Patheon shall be responsible for all the operations
that are marked with "X" in the column titled Patheon and that Cephalon shall be responsible for all the operations that are marked with "X" in the column titled "Cephalon." If marked with "(X)",
cooperation is required from the designated party. 

	

 	
 	

(a) General
	

 	
 	

[**]
	

 	
 	

(b) Raw Materials
	

 	
 	

[**]

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

29

 

	

 	
 	

(c) Bulk Manufacture
	

 	
 	

[**]
	

 	
 	

4. Packaging
	

 	
 	

[**]
	

 	
 	

(e) Testing and Release of Finished Product
	

 	
 	

[**]
	

 	
 	

(f) Stability Testing
	

 	
 	

[**]

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

30

 
 
 

ARTICLE 14
  
    COMPLIANCE BETWEEN PRODUCT REGISTRATION AND THE
  MANUFACTURING PROCESS    
    

	14.1
	Technical
Changes

	(a)
	All
proposed process changes shall be communicated to Cephalon for initial review and approval. [**] shall be responsible for determining whether or not to
initiate registration variation procedures and for maintaining adequate control over the quality commitments of the marketing authorization made to the regulatory authorities by
[**] for Products.

	(b)
	Following
validation of a process change, [**] shall deliver a copy of the related validation report to [**] and the associated
stability data, if applicable, as it becomes available.

	14.2
	Labelling/Packaging
Material Changes

	14.3
	Cephalon
may initiate changes and shall review any Patheon-proposed changes to labelling or packing, including a change in the supplier of any labelling or packaging materials before
any such change may be implemented.

	14.4
	Other
Changes

	14.5
	Patheon
will communicate any proposed changes in storage or shipping to Cephalon for review and approval. Patheon will also inform the Cephalon of any planned changes in facilities
or equipment that may impact Product(s). 

 
 

ARTICLE 15
  BATCH RELEASE    
    

	15.1
	Batch
review and release shall be the responsibility of a Patheon qualified person who shall act in accordance with Patheon's standard operating procedures

	15.2
	For
each batch released by Patheon for sale by Cephalon, Patheon shall deliver to Cephalon a certificate of compliance, which certificate shall include a statement that the batch has
been manufactured in accordance with cGMPs and Cephalon's Technical Information.

	15.3
	Patheon
shall notify Cephalon within [**] in the event of any deviation during manufacture or when any test reveals contamination, lack of sterility or
degradation in any batch of Product. 

 
 

ARTICLE 16
  BATCH DOCUMENTATION    
    

	16.1
	Originals
of all batch documentation will be retained by Patheon for a period of [**].

	16.2
	At
the request of Cephalon, Patheon agrees to provide a copy of any of the executed batch documents relating to Products to Cephalon by facsimile or courier within
[**].

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

31

 
 
 

ARTICLE 17
  STABILITY    
    

	17.1
	Patheon
shall perform such stability testing as specified by the MSA and as described in a stability protocol agreed to by both Patheon and Cephalon.

	17.2
	If
a confirmed result indicates that a Product has failed to remain within stability specifications, Patheon will notify Cephalon within [**].

	17.3
	Stability
data will be provided by Patheon to Cephalon on an ongoing basis as agreed to by both parties.

	17.4
	In
the event that the MSA is terminated, Patheon will continue to provide Cephalon with stability data supporting the acceptability of the Product until [**]. 

 
 

ARTICLE 18
  VALIDATION    
    

	18.1
	[**]
is responsible for providing validated analytical methods and manufacturing procedures to [**].

	18.2
	If
such methods and procedures are not validated, the [**] may assist in validation development with the costs being borne by [**]. 

 
 

ARTICLE 19
  GENERAL    
    

	19.1
	Interpretation

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

	19.2
	Capitalized
terms not otherwise defined herein shall have the meaning specified in the MSA.

	19.3
	Responsible
Persons

	19.4
	Any
communications with respect to the subject matter of this Agreement shall be directed, in the first instance, to the person(s) identified in Schedule B hereton, and
subsequently as specified in the MSA.

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

32

   II. Scope  

        This Quality Manual applies to all contract operations by Patheon for Cephalon, West Chester, PA for production of Provigil 100mg and 200mg tablets. 

III. Quality System and Requirements  

        A. Manufacturing GMP Compliance 

	1.
	Premises

	a.
	PATHEON
will manufacture the PRODUCTS at approved PATHEON facilities and/or approved third parties.

	b.
	The
premises and equipment used to manufacture the PRODUCTS will be in compliance with the current regulatory requirements and in accordance with the approved PATHEON specifications.

	c.
	The
production of the PRODUCTS will be conducted in a suitably controlled environment and such facilities will be monitored for parameters critical to the process to demonstrate
compliance with cGMP.

	d.
	PATHEON
will maintain controlled access to the premises.

	2.
	Master
Production Records 

PATHEON
will manufacture in accordance with the master production record which will comply with the approved specifications. 

	3.
	Standard
Operating Procedures

	a.
	PATHEON
is responsible for maintaining any Standard Operating Procedures required to manufacture, test and store the PRODUCTS at PATHEON and in accordance with the cGMPs.

	4.
	Batch
Numbers 

The
convention for the PATHEON lot numbering system is: 

SOP
OPS 1026 

	5.
	Dates
of Manufacture and Expiration

	a.
	Date
of Manufacture—PATHEON will assign the Date of Manufacture based on the date of the first component addition.

	b.
	Expiration
Date—PATHEON will calculate the expiry date from the Date of Manufacture using the currently approved expiry period. The expiration date will be the last day of
the month based on the expiry period.

	6.
	Manufacturing
and Equipment Data

	a.
	PATHEON
is responsible for keeping records of equipment usage (previous PRODUCT produced in non-dedicated equipment), cleaning and any maintenance/calibration performed.

	7.
	Storage
and Shipment

	a.
	Storage—PATHEON
will ensure that the Product will be stored in accordance with its labeling. Storage conditions will be maintained such that the Product is not damaged or
contaminated. 

33

 

	b.
	Packaging
and Labeling for Transit—The PRODUCTS will be suitably packaged for transit, each pallet or outer container being labeled with: 

PRODUCT's
Approved Name 

PATHEON
Lot Number 

Quantity

	c.
	Mixing
of Products—PATHEON will maintain proper segregation of the PRODUCTS in accordance with PATHEON's procedures. Different lots of a single PRODUCT or different types
of PRODUCTS will not be mixed on a pallet.

	d.
	Shipment
of Product to Cephalon—Only approved, finished, labeled PRODUCTS will be shipped by PATHEON to Cephalon or Cephalon's agents. 

        B.
Quality Control 

	1.
	General 

The
testing activities for the PRODUCTS are to be performed by PATHEON in accordance with approved specifications. 

	2.
	Materials
obtained by PATHEON

	a.
	Materials
procured by PATHEON

	1.
	PATHEON
is responsible for ensuring that all material and components procured by PATHEON for use in the product are in full compliance with the specifications. Raw materials are given
a retest an expiry date upon the satisfactory completion of all initial testing. Retest analysis will be performed at defined time intervals to ensure the materials continue to meet the established
specifications.

	2.
	PATHEON
is responsible for ensuring that all materials are purchased from approved vendors and are stored and maintained in accordance with the labeling.

	3.
	Cephalon
may request a change in vendors through PATHEON's Supplier approval program.

	3.
	In-Process
and Finished Product Testing

	a.
	PATHEON
will perform all in-process and finished product testing listed in the specifications. A PATHEON QA representative will sign a Certificate of Compliance confirming
that the product has been manufactured, packaged, tested and meets the requirements of the Master Batch Record. See Schedule C for definition.

	b.
	Cephalon
may perform testing to confirm that PATHEON data is acceptable.

	c.
	Differences
in test results between Cephalon and PATHEON will be resolved in accordance with the MSA for problem resolution.

	4.
	Retain
Samples

	a.
	Active
Ingredients—PATHEON will retain samples of the active ingredients for at least [**] beyond the expiry period of the PRODUCTS in which used.
The amount of sample retained will be [**] the quantity required to carry out all of the tests required to determine if the material meets its specifications, with the
exception of sterility and pyrogen testing. (CFR 211.170a).

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

34

 

	b.
	Products—PATHEON
will retain samples of the PRODUCTS for at least [**] beyond the expiry period. The amount of sample retained will be
[**] the quantity required to carry out all of the tests required to determine if the material meets its specifications, with the exception of sterility and pyrogen testing.
(CFR 211.170b).

	5.
	Routine
Stability

	a.
	PATHEON
is responsible for maintaining a routine stability testing program for the PRODUCTS and will provide a stability report to CEPHALON [**]. At a minimum
[**] of each strength and in each package type will be placed on stability each year. The stability program will generally follow ICH guidelines. The stability protocol or any
changes must be approved by Cephalon.

	b.
	Stability
Failures—Any confirmed problems that arise as a result of the stability program will be immediately communicated by PATHEON to Cephalon.

	c.
	In
the event that the MSA is terminated, PATHEON will continue to provide Cephalon with stability data supporting the acceptability of the Product until [**]. 

        C.
Quality Assurance 

	1.
	Deviations
and Investigations

	a.
	Deviations—Any
deviation from the process during manufacture must be carefully explained and documented in the batch records, justified, and approved by PATHEON Quality
Assurance and Production Managers and included in the document package. Deviations that have the potential for product impact will be forward to Cephalon for Approval within
[**] following review by Patheon QA.

	2.
	Confirmed
Out-of-Specification (OOS) Investigations

	a.
	PATHEON
is responsible for investigating any testing performed that yields a confirmed out of specification result and to communicate to Cephalon within [**].
Each investigation will be reviewed by PATHEON's designated Quality person, and will follow the procedure established in the relevant PATHEON Standard Operating Procedure.

	3.
	Specification
Failures Investigations—PATHEON is responsible for investigating any test result or in-process test, which fails to meet specifications and to
communicate this finding to Cephalon within [**]. Each investigation will be reviewed and approved by PATHEON's designated Quality person and by Cephalon. The investigation
must document the impact of any failure on the safety, efficacy, or quality of the PRODUCT. Disposition of this product (accept, reject, reprocess, etc.) will be made based on the result of the
investigation.

	a.
	PATHEON
will notify CEPHALON of any batch of PRODUCTS rejected by PATHEON within [**].

	b.
	PATHEON
will notify CEPHALON within [**] if any problems are discovered that may impact PRODUCTS batch(s) previously shipped to CEPHALON. Any additional testing
and activity required to support the above investigations will be the responsibility of PATHEON.

	4.
	Batch
Disposition—For each batch PATHEON will provide, to Cephalon:

	a.
	A
Certificate of Analysis (see Schedule C for definition)

	b.
	A
Certificate of Compliance (see Schedule C for definition)

	c.
	Copies
of any exception documents (NCMRs, deviations, re-inspections, reworks, etc.) associated with the batch including the associated investigations.

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

35

 

	5.
	Product
Release 

Release
of the PRODUCTS is the absolute responsibility of CEPHALON Quality and will be undertaken by Cephalon based on CEPHALON's internal procedures, the documentation package provided by PATHEON,
and completion of any release testing required by CEPHALON Quality Control. Any problem discovered by Cephalon likely to cause rejection of the PRODUCTS will be communicated to PATHEON within
[**] from receipts of the documentation package provided by PATHEON. Product will initially be approved by PATHEON QA and placed in quarantine inventory. These lots will be
held pending subsequent approval by CEPHALON QA. 

	6.
	Product
Complaints and Recalls

	a.
	Product
Complaints—CEPHALON is responsible for receiving and initially investigating any PRODUCTS complaints. CEPHALON will notify PATHEON of any problems thought to be due
to manufacture, which are found during distribution of the product. When requested by CEPHALON, PATHEON will promptly perform investigations for these problems. Investigation reports will be forwarded
to CEPHALON within [**].

	b.
	Product
Recall—CEPHALON is responsible for instituting a PRODUCT recall due to any defect considered sufficiently serious. CEPHALON will notify PATHEON of any recall, which
may be due to the manufacturing of PRODUCTS. PATHEON will provide a rapid initial response and provide full support for product recall. CEPHALON will be responsible for any customer notification
required by a recall.

	7.
	Records
Retention

	a.
	PATHEON
will retain, at a minimum, batch production records for the PRODUCTS and materials through the expiry date of the PRODUCTS plus one year.

	b.
	At
the request of Cephalon, Patheon agrees to provide a copy of any of the executed batch documents relating to Products to Cephalon by facsimile or courier within two business days.

	8.
	QA
Presence in the Manufacturing Facility 

PATHEON
will maintain adequate QA presence in the manufacturing facility during the manufacture of the PRODUCTS to ensure compliance with GMPs. 

        D.
Regulatory Compliance 

	1.
	Regulatory
Inspections

	a.
	PATHEON
will immediately inform CEPHALON of any FDA inspections that may involve the PRODUCT.

	b.
	PATHEON
will immediately provide CEPHALON with copies of responses to any FDA audits that impact CEPHALON's product.

	c.
	CEPHALON
will inform PATHEON in writing of any FDA issue that impacts PATHEON's ability to manufacture the PRODUCTS.

	2.
	Regulatory
Actions

	a.
	CEPHALON
will notify PATHEON of any regulatory actions on the PRODUCTS that may impact PATHEON.

	b.
	PATHEON
is responsible for supporting all batch record investigations associated with regulatory actions.

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

36

 

	c.
	PATHEON
agrees to supply CEPHALON with any manufacturing, testing or storage data within [**], if requested, as the result of a regulatory inspection, or a
potential regulatory exposure, such as a recall or significant product complaint.

	3.
	Audits
by CEPHALON

	a.
	CEPHALON
will be allowed to audit or observe PATHEON manufacturing facilities in accordance with the MSA.

	b.
	PATHEON
will permit CEPHALON Quality to perform [**] standard GMP compliance [**] per year.

	c.
	An
exit meeting will be held with representatives from PATHEON and CEPHALON to discuss significant audit observations.

	d.
	CEPHALON
will provide a written report of all observations within [**] to PATHEON. Within [**] of the audit report receipt, PATHEON will
provide a written response to all findings that details corrective action to be implemented. PATHEON will follow up to ensure that all corrective actions are implemented. 

        E.
Dispute Resolution 

        In
the event that a dispute arises between PATHEON and CEPHALON in the nonconformity of a batch of the PRODUCTS, the appropriate Quality management from both companies shall in good
faith promptly attempt to reach an agreement. Whatever the outcome, CEPHALON Quality retains the right to determine Product disposition. Financial liability is determined in accordance with the MSA. 

        F.
Change Management 

	1.
	Controlled
Documentation

	a.
	All
manufacturing and testing will be performed in accordance with the specifications listed in the MSA. These specifications will be approved by PATHEON and CEPHALON.

	b.
	Any
changes to these specifications will be approved by PATHEON and CEPHALON prior to implementation.

	1)
	Cephalon
will route and approve revised specifications in accordance with CEPHALON document approval practices.

	2)
	CEPHALON's
QA representative will sign the PATHEON Change Request form indicating CEPHALON approval.

	3)
	Any
special instructions required to implement a specific change request (CR) such as hold pending prior FDA approval, perform stability testing, etc. will be attached to the CR when
returned to PATHEON.

	2.
	Change
Control Process

	a.
	Changes
initiated by PATHEON will use the PATHEON change control procedure and will be subsequently approved by Cephalon prior to implementation.

	b.
	Changes
initiated by CEPHALON will be submitted in writing to PATHEON. PATHEON will initiate the change request process and the changes will be approved by CEPHALON prior to
implementation.

	3.
	Specification
Distribution 

        Once
revised specifications are approved PATHEON will forward copies to CEPHALON. 

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

37

 

        G.
Product and Process Validation 

        PATHEON
shall maintain an appropriate validation program and change control procedures to ensure all applicable: 

	•
	Processing
equipment and their supporting systems;

	•
	Computer
systems;

	•
	Test
methods;

	•
	Equipment
cleaning 

        involved
in the manufacture, testing, storage, and distribution of Products are qualified/approved for the specified uses. This program shall include facilities/utilities that directly
support related manufacturing operations. Computer systems that involve a product's conformance to specifications, lot traceability, and/or the ability of PATHEON to meet any regulatory requirements
must also be validated. PATHEON shall have appropriate validation protocols and/or packages which contain protocol objectives, a description of the product/process/ equipment to be evaluated,
parameters to be investigated, test methods, sampling strategy as pertinent, and acceptance criteria. 

        H.
Annual Product Review, Annual Report and Drug Listing 

	1.
	Annual
Product Review 

        PATHEON
shall complete an Annual Product Review (APR) of batch records and test reports for each Product lot completed. This APR shall list all lot numbers processed, and a written
review summary of products quality performance parameters, including complaints, recalls, returned goods, exception
reports with associated corrective actions, and trend analysis. CEPHALON will develop the complaint, recall, and returned goods data for inclusion in the APR, and subsequent submission. 

	2.
	Annual
Report 

        CEPHALON
is responsible for preparing any Annual Report as required by applicable regulations, including 21 CFR 314.7(g)(3), 314.81(b)(2), and/or 601.12(d), (f)(3). At least
[**] before the Annual Report due date, CEPHALON shall request in writing from PATHEON the chemistry, manufacturing, and controls data required for submission of the Annual
Report. PATHEON will provide the requested information to Cephalon within [**]. 

	3.
	Annual
Manufacturing Process Change Report 

        CEPHALON
is responsible for preparing the Annual Manufacturing Process Change Report as required by 21 CFR 601.12(d). At least [**] before the Annual Report due
date, CEPHALON will request in writing from PATHEON the chemistry, manufacturing, and controls data required for submission of the Annual Report. PATHEON will provide the requested information to
CEPHALON within [**]. 

	4.
	Drug
Listing 

        PATHEON
is responsible for drug listing as the manufacturer of the PRODUCTS, while CEPHALON is responsible for drug listing as the distributor of the PRODUCTS. CEPHALON will provide
PATHEON with all required information needed by them for their listing. 

        I.
Shipping Instructions 

	1.
	Instructions
for Shipping to CEPHALON

	**
	Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

38

 

	2.
	Provigil
stock product will be shipped from PATHEON to the following address: 

        Cord
Logistics, Inc. 

        Sullivan
S of Cephalon 

        15
Ingram Blvd. Suite 100 

        LaVergne,
TN 37086 

	3.
	Provigil
samples will be shipped from PATHEON to the following address: 

        Promotech 

        408
South Pierce Avenue 

        Louisville,
CO 80027 

	 	 	CEPHALON, INC.
	

 	
 	

By:	
 	

	

 	
 	

Name:	
 	

	

 	
 	

Title:	
 	

	

 	
 	

Date:	
 	

	

 	
 	
PATHEON
	

 	
 	

By:	
 	

	

 	
 	

Name:	
 	

	

 	
 	

Title:	
 	

	

 	
 	

Date:	
 	

39

  

 
 

SCHEDULE A
  PRODUCT(S)    
    

	Product(s)
	 	Galenic Form
	 	Dosage (Strength)

	PROVIGIL TABLETS	 	modafinil	 	100mg
	PROVIGIL TABLETS	 	modafinil	 	200mg

40

 
 
 

SCHEDULE B
  QUALITY CONTACTS    
    

	Client	 	 
	Cephalon:	 	Patheon:
	Attention:	 	Attention:
	Fax No.:	 	Fax No.:

	Title
	 	Individual
	 	Phone
	 	Fax
	 	E-Mail

	Contract Management	 	[**]	 	[**]	 	[**]	 	[**]
	Schedules & Forecasts	 	[**]	 	[**]	 	[**]	 	[**]
	Product Complaints	 	[**]	 	[**]	 	[**]	 	[**]
	Medical	 	[**]	 	[**]	 	[**]	 	[**]
	Documentation	 	[**]	 	[**]	 	[**]	 	[**]
	Labeling	 	[**]	 	[**]	 	[**]	 	[**]
	Regulatory	 	[**]	 	[**]	 	[**]	 	[**]
	Technical Support	 	[**]	 	[**]	 	[**]	 	[**]
	Quality	 	[**]	 	[**]	 	[**]	 	[**]
	Cert Approval	 	[**]	 	[**]	 	[**]	 	[**]

**  Portions
of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

41

 
 
 

SCHEDULE C
  Release Documentation    
    

A Certificate of Analysis (C of A)  

        This document will include the name of the PRODUCT, the batch number, and the date of manufacture. The C of A will also list the acceptance criteria for each
release test performed and the
associated result for each test, along with the test identifier number (Standard Test Method). The C of A will be signed by an appropriate QA representative. 

Certificate of Compliance (C of C)  

        This document will attest to the fact that the batch of Products was made in accordance with the master batch records, the relevant product specifications and the
related Basic Operating Procedures. This C of C will include the batch quantity approved, the batch yield, and the expiration date. It will also include a listing of all exception documents
(deviations, Non-conformances, re-inspection, etc.) associated with the batch. The C of C will be signed by an appropriate QA representative. 

42

 
 
 

SCHEDULE H
  CEPHALON'S TRADEMARKS    
    

          

  

Cephalon®  

 Provigil®  

43

QuickLinks

Manufacturing Services Agreement January 1, 2003

Table of Contents

MANUFACTURING SERVICES AGREEMENT

ARTICLE 1 INTERPRETATION

ARTICLE 2 PATHEON'S MANUFACTURING RESPONSIBILITIES

ARTICLE 3 CEPHALON'S OBLIGATIONS

ARTICLE 4 CONVERSION FEES AND COMPONENT COSTS

ARTICLE 5 ORDERS, DELIVERY, INVOICING, PAYMENT, PRODUCT DEFICIENCIES

ARTICLE 6 CO-OPERATION

ARTICLE 7 TERM AND TERMINATION

ARTICLE 8 REPRESENTATIONS, WARRANTIES AND COVENANTS

ARTICLE 9 REMEDIES AND INDEMNITIES

ARTICLE 10 CONFIDENTIALITY

ARTICLE 11 DISPUTE RESOLUTION

ARTICLE 12 TRADEMARKS

ARTICLE 13 MISCELLANEOUS

SCHEDULE A PRODUCTS, MINIMUM RUN QUANTITY, MINIMUM ANNUAL VOLUME AND FEES

SCHEDULE B STABILITY TESTING FEES

SCHEDULE C ACTIVE MATERIALS

SCHEDULE D ACTIVE MATERIALS VALUE

SCHEDULE E BATCH NUMBERING AND EXPIRATION DATES

SCHEDULE F TECHNICAL DISPUTE RESOLUTION

SCHEDULE G FORM OF TECHNICAL AGREEMENT

ARTICLE 13 TECHNICAL AGREEMENT

ARTICLE 14 COMPLIANCE BETWEEN PRODUCT REGISTRATION AND THE MANUFACTURING PROCESS

ARTICLE 15 BATCH RELEASE

ARTICLE 16 BATCH DOCUMENTATION

ARTICLE 17 STABILITY

ARTICLE 18 VALIDATION

ARTICLE 19 GENERAL

SCHEDULE A PRODUCT(S)

SCHEDULE B QUALITY CONTACTS

SCHEDULE C Release Documentation

SCHEDULE H CEPHALON'S TRADEMARKSExhibit
4.12

 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED
FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE “ACT”).  SUCH SECURITIES
MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF REGISTRATION OR AN EXEMPTION
THEREFROM. RIGEL PHARMACEUTICALS, INC. MAY REQUIRE AN OPINION OF COUNSEL
REASONABLY ACCEPTABLE TO IT THAT A PROPOSED TRANSFER OR SALE IS IN COMPLIANCE
WITH THE ACT.

 

THE SALE, TRANSFER OR VOTING OF THE SECURITIES
REPRESENTED HEREBY IS RESTRICTED BY THE TERMS OF A SECOND INVESTOR RIGHTS
AGREEMENT BY AND AMONG RIGEL PHARMACEUTICALS, INC. AND THE INVESTORS NAMED
THEREIN. COPIES OF THE AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST
MADE BY THE HOLDERS OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF RIGEL
PHARMACEUTICALS, INC. AT THE PRINCIPAL EXECUTIVE OFFICES OF RIGEL
PHARMACEUTICALS, INC.

 

RIGEL
PHARMACEUTICALS, INC.

 

COMMON
STOCK PURCHASE WARRANT

 

	
  Warrant No. CS-15

  	
   

  	
  217,686 Shares

  
	
  June 26, 2003

  	
   

  	
   

  

 

1.     Issuance.  For value received, this Warrant is issued
to Alta BioPharma
Partners II, L.P., by Rigel Pharmaceuticals, Inc.,
a Delaware corporation (hereinafter with its successors called the “Company”),
pursuant to the terms and conditions of that certain Common Stock and Warrant
Purchase Agreement, dated as of April 29, 2003, by and among the Company and
the investors listed on Schedule A thereto (the “Purchase Agreement”).

 

2.     Purchase
Price; Number of Shares.  The
registered holder of this Warrant (the “Holder”), commencing on the date hereof,
is entitled upon surrender of this Warrant, with the subscription form annexed
hereto duly executed, at the principal office of the Company, to purchase from
the Company two hundred seventeen thousand six hundred eighty-six  (217,686) fully paid and nonassessable
shares (the “Shares”) of common stock, $.001 par value per share, of the
Company (the “Common Stock”), at a price per share of $5.76 (the “Warrant
Price”).  Until such time as
this Warrant is exercised in full or expires, the Warrant Price and the
securities issuable upon exercise of this Warrant are subject to adjustment as
hereinafter provided.  The person or
persons under whose name or names any certificate representing Shares shall be
deemed to have become the holder of record of the Shares represented thereby as
at the close of business on the date this Warrant is exercised with respect to
such Shares, whether or not the transfer books of the Company shall be closed.

 

3.     Payment
of Purchase Price.  The Purchase
Price (as defined below) may be paid: (i) by certified or bank check or by wire
transfer of immediately available funds to an account designated by the
Company; (ii) by the surrender by the Holder to the Company of any

 

1

 

promissory notes or other
obligations issued by the Company, with all such notes and obligations so
surrendered being credited against the Purchase Price in an amount equal to the
principal amount thereof plus accrued interest to the date of surrender; (iii)
exercise of the “net issue election” right provided for in Section 4; or (iv)
by any combination of the foregoing. The “Purchase
Price” shall mean the amount equal to the then applicable Warrant
Price multiplied by the number of Shares then being purchased.

 

4.     Net
Issue Election.  The Holder may
elect to receive, without the payment by the Holder of any additional
consideration, shares of Common Stock equal to the value of this Warrant or any
portion hereof by the surrender of this Warrant or such portion to the Company,
with the net issue election notice annexed hereto duly executed, at the
principal office of the Company. 
Thereupon, the Company shall issue to the Holder such number of fully
paid and nonassessable shares of Common Stock as is computed using the following
formula:

 

 

	
   

  	
  X =

  	
  Y (A – B)

  	
   

  
	
   

  	
   

  	
  A

  	
   

  

 

where:                                                             X
=                             the
number of shares of Common Stock to be issued to the Holder pursuant to this
Section 4.

 

                                                                                                Y
=                              the
number of shares of Common Stock covered by this Warrant in respect of which
the net issue election is made pursuant to this Section 4.

 

                                                                                                A
=                            the
Fair Market Value (defined below) of one share of Common Stock, as determined
at the time the net issue election is made pursuant to this Section 4.

 

                                                                                                B
=                              the
Warrant Price in effect under this Warrant at the time the net issue election
is made pursuant to this Section 4.

 

“Fair Market Value” of a
share of Common Stock as of a particular date (the “Determination Date”) shall mean the average of the closing
or last reported sale prices of the Common Stock as reported on the Nasdaq
National Market over the 30-day period ending five business days prior to the
Determination Date; provided, however, that if (i) the Common
Stock is neither traded on the Nasdaq National Market nor on a national
securities exchange, then Fair Market Value shall be the average of the closing
or last reported sale prices of the Common Stock over the 30-day period ending
five business days prior to the Determination Date reflected in the
over-the-counter market, as reported by the National Quotation Bureau, Inc. or
any organization performing a similar function, or if closing prices are not
then routinely reported for the over-the-counter market, the average of the
last bid and asked prices of the Common Stock over the 30-day period ending
five business days prior to the Determination Date and (ii) if there is no
public market for the Common Stock, then Fair Market Value shall be determined
in good faith by the Company’s Board of Directors.

 

5.     Partial
Exercise.  This Warrant may be
exercised in part, and the Holder shall be entitled to receive a new warrant,
which shall be dated as of the date of this Warrant, covering the number of
Shares in respect of which this Warrant shall not have been exercised.

 

2

 

6.     Fractional
Shares.  In no event shall any
fractional share of Common Stock be issued upon any exercise of this
Warrant.  If, upon exercise of this
Warrant as an entirety, the Holder would, except as provided in this Section 6,
be entitled to receive a fractional share of Common Stock, then the Company
shall pay in lieu thereof, the Fair Market Value of such fractional share in
cash.

 

7.     Expiration
Date; Early Termination.  This
Warrant or any Successor Warrant (as defined in Section 10 below) shall expire
on the close of business on June 26, 2008 (the “Expiration Date”), and shall be void thereafter.

 

8.     Reserved
Shares; Valid Issuance.  The Company
covenants that it will at all times from and after the date hereof reserve and
keep available such number of its authorized shares of Common Stock, free from
all preemptive or similar rights therein, as will be sufficient to permit the
exercise of this Warrant in full into shares of Common Stock upon such
exercise.  If at any time prior to the
Expiration Date the number of authorized but unissued shares of Common Stock
shall not be sufficient to permit exercise of this Warrant, the Company shall
take such corporate action as may, in the opinion of its counsel, be necessary
to increase its authorized but unissued shares of Common Stock to such number
of shares as shall be sufficient for such purposes. The Company further
covenants that such shares as may be issued pursuant to such exercise will,
upon issuance, be duly and validly issued, fully paid and nonassessable and
free from all taxes, liens and charges with respect to the issuance thereof.

 

9.     Stock
Splits and Dividends.  If after the
date hereof the Company shall subdivide the Common Stock, by split-up or
otherwise, combine the Common Stock or issue additional shares of Common Stock
in payment of a stock dividend on the Common Stock, then the number of Shares
issuable upon the exercise of this Warrant shall forthwith be proportionately
increased in the case of a subdivision or stock dividend, or proportionately
decreased in the case of a combination, and the Warrant Price shall forthwith
be proportionately decreased in the case of a subdivision or stock dividend, or
proportionately increased in the case of a combination.

 

10.  Mergers and Reclassifications.

 

(a)   If
after the date hereof the Company shall enter into any Reorganization (as
hereinafter defined), then, as a condition of such Reorganization, lawful
provisions shall be made, and duly executed documents evidencing the same from
the Company or its successor shall be delivered to the Holder (a “Successor Warrant”), so that the Holder
shall thereafter have the right to purchase, at a total price not to exceed
that payable upon the exercise of this Warrant in full, the kind and amount of
shares of stock and other securities and property receivable upon such
Reorganization by a holder of the number of shares of Common Stock that might
have been purchased by the Holder immediately prior to such Reorganization, and
in any such case appropriate provisions shall be made with respect to the
rights and interest of the Holder to the end that the provisions hereof
(including without limitation, provisions for the adjustment of the Warrant
Price and the number of shares issuable hereunder and the provisions relating
to the net issue election) shall thereafter be applicable in relation to any
shares of stock or other securities and property thereafter deliverable upon
exercise hereof.

 

3

 

(b)   For
the purposes of this Section 10, the term “Reorganization” shall include
without limitation any reclassification, capital reorganization or change of
the Common Stock (other than as a result of a subdivision, combination or stock
dividend provided for in Section 9 hereof), any consolidation of the Company
with, or merger of the Company into, another corporation or other business
organization (other than a merger in which the Company is the surviving
corporation and which does not result in any reclassification or change of the
outstanding Common Stock), or any sale or conveyance to another corporation or
other business organization of all or substantially all of the assets of the
Company

 

11.  Certificate
of Adjustment. Whenever the Warrant Price is adjusted, as herein provided,
the Company shall promptly deliver to the Holder a certificate of the Company’s
Chief Financial Officer setting forth the Warrant Price after such adjustment
and setting forth a brief statement of the facts requiring such adjustment.

 

12.  Notices
of Record Date, Etc.  In the event
of:

 

(a)   any
taking by the Company of a record of the holders of any class of securities for
the purpose of determining the holders thereof who are entitled to receive any
dividend or other distribution, or any right to subscribe for, purchase, sell
or otherwise acquire or dispose of any shares of stock of any class or any
other securities or property, or to receive any other right;

 

(b)   any
reclassification of the capital stock of the Company, capital reorganization of
the Company, consolidation or merger involving the Company or sale or
conveyance of all or substantially all of its assets; or

 

(c)   any
voluntary or involuntary dissolution, liquidation or winding-up of the Company;

 

then in each such event the Company will provide or cause to be
provided to the Holder a written notice thereof.  Such notice shall be provided at least 15 calendar days prior to
the date specified in such notice on which any such action is to be taken.

 

13.  Representations,
Warranties and Covenants.  This
Warrant is issued and delivered by the Company and accepted by each Holder on
the basis of the following representations, warranties and covenants made by
the Company:

 

(a)   The
Company has all necessary authority to issue, execute and deliver this Warrant
and to perform its obligations hereunder. 
This Warrant has been duly authorized, issued, executed and delivered by
the Company and is the valid and binding obligation of the Company, enforceable
in accordance with its terms, except as enforceability may be limited by
bankruptcy, insolvency, reorganization or other similar laws of general
application affecting the enforcement of the Holder’s rights or by general
equity principals or public policy concerns.

 

(b)   The
Shares have been duly authorized and reserved for issuance by the Company and,
when issued in accordance with the terms hereof, will be validly issued, fully
paid and nonassessable.

 

4

 

14.  Amendment
and Waiver.  The terms of this
Warrant may be amended, modified or waived only with the written consent of the
party against which enforcement of the same is sought.

 

15.  Representations
and Covenants of the Holder.  This
Warrant has been entered into by the Company in reliance upon the following representations
and covenants of the Holder, which by its execution hereof the Holder hereby
confirms:

 

(a)   The
Holder is an “accredited investor” as defined in Regulation D under the
Securities Act of 1933, as amended (the “Securities
Act”), and the Holder is knowledgeable, sophisticated and
experienced in making, and is qualified to make decisions with respect to,
investments in shares presenting an investment decision like that involved in
the purchase of the Shares and the Warrant, including investments in securities
issued by the Company and investments in comparable companies, and has
requested, received, reviewed and considered all information it deemed relevant
in making an informed decision to purchase the Warrant;

 

(b)   The
Holder is acquiring the Warrant in the ordinary course of its business and for
its own account for investment only and with no present intention of
distributing the Warrant or any of the Shares or any arrangement or
understanding with any other persons regarding the distribution of the Warrant
or the Shares; and

 

(c)   The
Holder will not, directly or indirectly, offer, sell, pledge, transfer or
otherwise dispose of (or solicit any offers to buy, purchase or otherwise
acquire or take a pledge of) the Warrant or any of the Shares except in
compliance with the Securities Act, applicable state securities laws and the
respective rules and regulations promulgated thereunder.

 

16.  Notices,
Transfers, Etc.

 

(a)   Any
notice or written communication required or permitted to be given to the Holder
may be given by certified mall or delivered to the Holder at the address most
recently provided by the Holder to the Company.

 

(b)   Subject
to compliance with applicable federal and state securities laws and any other
contractual restrictions between the Company and the Holder contained in the
Purchase Agreement or that certain Second Investor Rights Agreement, dated as
of the date hereof, by and among the Company and the investors named therein,
this Warrant may be transferred by the Holder with respect to any or all of the
Shares purchasable hereunder.  Upon
surrender of this Warrant to the Company, together with the assignment notice
annexed hereto duly executed, for transfer of this Warrant as an entirety by
the Holder, the Company shall issue a new warrant of the same denomination to
the assignee.  Upon surrender of this
Warrant to the Company, together with the assignment hereof properly endorsed,
by the Holder for transfer with respect to a portion of the Shares, the Company
shall issue a new warrant to the assignee, in such denomination as shall be
requested by the Holder hereof, and shall issue to such Holder a new warrant
covering the number of Shares in respect of which this Warrant shall not have
been transferred.

 

(c)   The
Company acknowledges and agrees that an opinion of counsel shall not be
required upon the transfer by the Holder of any securities to an “Affiliate”
(as defined in Rule

 

5

 

12b-2 of the rules and
regulations promulgated under the Securities and Exchange Act of 1934, as
amended) of such Holder.

 

(d)   In
case this Warrant shall be mutilated, lost, stolen or destroyed, the Company
shall issue a new warrant of like tenor and denomination and deliver the same
(i) in exchange and substitution for and upon surrender and cancellation of any
mutilated Warrant or (ii) in lieu of any Warrant lost, stolen or destroyed,
upon receipt of an affidavit of the Holder or other evidence reasonably
satisfactory to the Company of the loss, theft or destruction of such Warrant
and an indemnification of loss by the Holder in favor of the Company.

 

17.  Transfer
to Comply with the Securities Act.   This Warrant may not be exercised and neither this Warrant nor any
of the Shares, nor any interest in either, may be offered, sold, assigned,
pledged, hypothecated, encumbered or in any other manner transferred or
disposed of, in whole or in part, except in compliance with applicable United
States federal and state securities laws and the terms and conditions hereof.  Each Warrant shall bear a legend in
substantially the same form as the legend set forth on the first page of this
Warrant.  Each certificate for Shares
issued upon exercise of this Warrant, unless at the time of exercise such
Shares are acquired pursuant to a registration statement that has been declared
effective under the Securities Act and applicable blue sky laws, shall bear
legends substantially in the following form:

 

“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN
ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “ACT”).  SUCH
SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF REGISTRATION OR AN
EXEMPTION THEREFROM. RIGEL PHARMACEUTICALS, INC. MAY REQUIRE AN OPINION OF
COUNSEL REASONABLY ACCEPTABLE TO IT THAT A PROPOSED TRANSFER OR SALE IS IN
COMPLIANCE WITH THE ACT.”

 

“THE SALE, TRANSFER OR VOTING OF THE SHARES
REPRESENTED BY THIS CERTIFICATE IS RESTRICTED BY THE TERMS OF A SECOND INVESTOR
RIGHTS AGREEMENT BY AND AMONG RIGEL PHARMACEUTICALS, INC. AND THE INVESTORS
NAMED THEREIN. COPIES OF THE AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN
REQUEST MADE BY THE HOLDERS OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF
RIGEL PHARMACEUTICALS, INC. AT THE PRINCIPAL EXECUTIVE OFFICES OF RIGEL PHARMACEUTICALS,
INC.”

 

Any certificate for any Shares issued at any time in
exchange or substitution for any certificate for any Shares bearing such
legends (except a new certificate for any Shares issued after the acquisition
of such Shares pursuant to a registration statement that has been declared
effective

 

6

 

under the Securities Act) shall also bear such legends
unless, in the opinion of counsel for the Company, the Shares represented
thereby need no longer be subject to the restriction contained herein.  The provisions of this Section 17 shall be
binding upon all subsequent holders of certificates for Shares bearing the
above legends and all subsequent holders of this Warrant, if any.

 

18.  Rights
of the Holder.  The Holder shall not, by virtue hereof, be
entitled to any rights of a stockholder of the Company, either at law or
equity, and the rights of the Holder are limited to those expressed in this
Warrant.  Nothing contained in this
Warrant shall be construed as conferring upon the Holder hereof the right to
vote, to consent or to receive notice as a stockholder of the Company on any
matters or with respect to any rights whatsoever as a stockholder of the
Company.  No dividends or interest shall
be payable or accrued in respect of this Warrant or the interest represented
hereby or the Shares purchasable hereunder until, and only to the extent that,
this Warrant shall have been exercised in accordance with its terms.

 

19.  No
Impairment.  The Company will not,
by amendment of its Amended and Restated Certificate of Incorporation or
through any reclassification, capital reorganization, consolidation, merger,
sale or conveyance of assets, dissolution, liquidation, issue or sale of
securities or any other voluntary action, avoid or seek to avoid the observance
of performance of any of the terms of this Warrant, but will at all times in
good faith assist in the carrying out of all such terms and in the taking of
all such action as may be necessary or appropriate in order to protect the
rights of the Holder.

 

20.  Governing
Law.  The provisions and terms of
this Warrant shall be governed by and construed in accordance with the internal
laws of the State of California.

 

21.  Successors
and Assigns.  This Warrant shall be
binding upon the Company’s successors and assigns and shall inure to the
benefit of the Holder’s successors, legal representatives and permitted
assigns.

 

22.  Business
Days.  If the last or appointed day
for the taking of any action required or the expiration of any rights granted
herein shall be a Saturday or Sunday or a legal holiday in California, then
such action may be taken or right may be exercised on the next succeeding day
that is not a Saturday or Sunday or such a legal holiday.

 

23.  Severability.  If one or more provisions of this Warrant are
held to be unenforceable under applicable law, such provision shall be excluded
from this Warrant, and the balance of the Warrant shall be interpreted as if
such provision were so excluded and shall be enforceable in accordance with its
terms.

 

7

 

In Witness Whereof, the Company has duly
caused this Warrant to be signed by its duly authorized officer and to be dated
as of the date first written above.

 

 

	
   

  	
  Company:

  
	
   

  	
   

  
	
   

  	
  Rigel Pharmaceuticals, Inc.

  
	
   

  	
   

  
	
   

  	
  By:

  	
    /s/ James M. Gower

  	
   

  
	
   

  	
   

  	
  James M. Gower

  
	
   

  	
   

  	
  Chairman and Chief Executive Officer

  
					

 

8

 

Notice of Exercise

 

(1)           The undersigned hereby:

 

[             ]                elects to purchase
                  
shares of Common Stock of the Company pursuant to the terms of the attached
Warrant, and tenders herewith payment of the purchase price of such shares in
full, together with all applicable transfer taxes, if any.

 

[             ]                elects to exercise
its net issuance rights pursuant to Section 4 of the attached Warrant with
respect to
                     
shares of Common Stock, and shall tender payment of all applicable transfer
taxes, if any.

 

(2)           Please
issue a certificate or certificates representing said shares of Common Stock in
the name of the undersigned or in such other name as is specified below:

 

	
   

  	
   

  	
   

  
	
  (Name)

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  (Address)

  

 

(3)           The undersigned represents that the
aforesaid shares are being acquired for the account of the undersigned for
investment and not with a view to, or for resale in connection with, the
distribution thereof and that the undersigned has no present intention of
distributing or reselling such shares, all except as in compliance with
applicable securities laws. 

 

	
   

  	
   

  	
   

  	
   

  
	
  (Date)

  	
   

  	
  (Signature)

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (Print name)

  	
   

  

 

 

Assignment

 

For value received
                                                                                                                                    
hereby sells, assigns and transfers unto
                                                                                                                                                                                   

 

[Please print or type the name
and address of Assignee]

 

 

the within Warrant, and does hereby irrevocably constitute and appoint
                                  
                                
its attorney to transfer the within Warrant on the books of the within named
Company with full power of substitution on the premises.

 

	
  Dated:

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  In the Presence of:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]